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Often correlated to a poor prognosis and increased mortality in cancer patients, hypoxic 
adaptation in tumors is mainly endorsed by Hypoxia Inducible Factor (HIF-1α). Under 
conditions of oxygen scarcity, this transcription factor triggers the expression of specific 
target genes implicated in glycolysis, neoangiogenesis and survival. Although hypoxia 
signalling constitutes an interesting target, the development of therapeutics has been limited 
by the high rate of drug resistance.  
We previously showed the lack of a respiratory Complex I causes the accumulation of αKG 
associated to destabilization of HIF-1α that render cancer cells unable to adapt to hypoxia as 
a result of PHDs stimulation by their substrate αKG, ultimately resulting in a blocked tumor 
growth in vivo. This project aims to propose a selective metabolic approach based on the 
supplementation of αKG as an anticancer agent. To counter αKG limited permeability, the 
ketoacid was coupled to distinct hydrophobic carriers giving 7 ester analogues of αKG 
(αKGlogues) generated for the purpose of this study. The analogues were screened for their 
capacity to oppose to HIF-1α stabilisation under hypoxic conditions and to selectively 
hamper cancer cells growth without marked toxicity on non-cancer counterparts. This 
approach allowed us to select αKG-PP as a potent and safe αKGlogue since it limits HIF-1α 
stabilisation at long term, selectively impairs cancer cells proliferation and their in vitro 
tumorigenic properties while being well tolerated by the non-cancer counterparts. Further, a 
synergistic effect of the hydrophobic carrier, independent of HIF-1α, was also unveiled. 
Metabolomics analysis revealed an intracellular peak in αKG upon treatment coupled to a 
rearrangement in other TCA cycle intermediates. αKG accumulation correlated with Raptor 
hyperphosphorylation at short-term, suggesting the αKGlogue mediates its effect through the 
block of mTORC1 signalling and protein synthesis. Finally, in the perspective of an αKG-
based anticancer therapy, the selected analogue displayed anti-proliferative properties on 3D 
cancer spheroids and a Drosophila melanogaster cancer model. The present data highlight 
the safety and potency of the selected molecule both in vitro and in vivo, as well as the 
potential of αKG-based treatment to consider for future combinatory therapies to tackle 

































5-hmC: 5-hydroxymethylcytosine  
5fC: 5-formylcytosine  
5caC : 5-carboxylcytosine  
Ac-CoA : Acetyl-CoA 
ALDA/ALDC: aldolase A and C 
AML: Acute myeloide leukemias  
AMPK: AMP activated kinase 
Asn: Asparagine 
ATP: Adenosine triphosphate 
ARNT: Aryl Hydrocarbon Receptor nuclear translocator 
BHD: Birt-Hogg-Dubé syndrome  
bHLH-PAS: helix–loop–helix - per-arnt-sim 
CI: Complex I 
CA9: Carbonic anhydrase 
CBP: CREB binding protein  
ccRCC: Clear cell renal cell carcinoma 
CH: Cysteine/histidine rich domain  
CTAD: C-transactivation domain  
DMSO: Dimethyl sulfoxide  
EDTA: Ethylenediaminetetraacetic acid 
EMT: Epithelial-to-mesenchymal transition 
ETC: Electron transport chain 
FA: Fumarate 
FADH2: Flavine adenine dinucleotide 
FAO: Fatty acids β-oxidation  
FH: Fumarate hydratase 
FIH1: Factor inhibiting HIF 
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase  
GBBH: ɤ-butyrobetain hydroxylase  
GDH : Glutamate dehydrogenase 
GLS: Glutaminase 
GT: Glutamine transaminase  
GOT: Glutamate oxaloacetate transaminases 
GPT: Glutamate pyruvate transaminases 
GLUT: Glucose transporter  
GS: Glutamine synthase  
HAPs: Hypoxia-activated-prodrugs  
HDAC: Histone deacetylase   
LC-MS: Liquid chromatography-Mass spectrometry  
KMV: 3-methyl, 2-oxovaleric acid 
HIF: Hypoxia inducible factor 
His: Histidine 
HK: Hexokinase 
HRE: Hypoxia responsive element 
IDH: isocitrate dehydrogenase 
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IGF: Insulin-like growth factor  
IMM: Inner mitochondrial membrane 
IMS: Inter-membrane mitochondrial space 
JmjC: Jumonji-containing domain 
JHDM: JmjC histone demethylases 
KDM: Lysine Demethylase 
LDHA: Lactate dehydrogenase A 
LZIP: Leucine-zipper domain 
MCT: Mono-lactate transporter 
MDH: Malate dehydrogenase 
MDM2: Mouse double minute 2 
mtDNA: Mitochondrial DNA 
MMPs: Metallo-proteinases 
mTOR: Mammalian/Mechanistic Target of rapamycin  
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
nDNA: nuclear DNA 
NADH: Nicotinamide adenine dinucleotide  
NMLH: N-methyllysine hydroxylase  
NADPH: Nicotinamide adenine dinucleotide phosphate  
NTAD: N-transactivation domain  
OAA: Oxaloacetate 
ODDDs: Oxygen-degradation dependent domain  
OMM: Outer mitochondrial membrane 
OXPHOS: Oxidative phosphorylation 
P5C: Pyrroline-5-Carboxylate  
P4H: Proline 4(R)-hydroxylase  
PBS: Phosphate Buffer Saline  
PFK: Phosphofructokinase 
PKM2: Pyruvate Kinase M2 
PDK: Pyruvate dehydrogenase kinase 
PDH: Pyruvate dehydrogenase 
PHD: Prolyl hydroxylase 
Pro: Proline 
PVDF: Polyvinylidene floride  
pVHL: Von Hippel Lindau protein 
ROS: Reactive oxygen species 
SDS-PAGE : Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SA: Succinate 
SDH: succinate dehydrogenase 
SRB: Sulforhodamine B 
TBS: Tris Buffered Saline 
TCA: Trichloroacetic acid  
TCA cycle: Tricarboxylic acids cycle  
TETs: Ten Eleven Translocases  
TDG: Thymine-DNA glycosylase 
TLC: Thin Layer Chromatography 
TM-HIF: Triple-mutant HIF1A  
VDAC: Voltage-dependant anion channel  





αKGDDs: αKG-dependent dioxygenases 
αKGDHC: α-ketoglutarate dehydrogenase complex  
αKG-G: α-ketoglutarate geraniol 
αKG-N: α-ketoglutarate nerol 
αKG-L: α-ketoglutarate linelol 
αKG-Cl: α-ketoglutarate 2, 4-dichloride  
αKG-tB: α-ketoglutarate terbutyl  
αKG-P: α-ketoglutarate phenyl 











































Hallmarks of cancer  
Long thought to be a genetic disease, constant progress in understanding cancer biology now 
provide more insight into the multifactorial character of this burden. Malignant 
transformation occurs in a subset of neoplastic precursors as a result of genetic and epigenetic 
insults leading to uncontrolled expansion, to ultimately form complex tissues with a deranged 
architecture. A consistent body of evidence sustain that cancer onset happens as a succession 
of multiple processes (Hanahan and Weinberg 2000). Additionally, tumors are characterised 
by their high heterogeneity in terms of cellular population. Cancer cells were shown to 
actively cooperate with their recruited associated stromal cells and vice versa to foster tumor 
formation, progression and response to therapy. In this context, the diverse and complex 
characteristics that govern tumorigenesis have been elegantly stratified by Hanahan and 
Weinberg who defined 6 main capabilities as cancer cells hallmarks (Hanahan and Weinberg 
2011). Through their progression towards malignancy cancer cells acquire the capacity to 
sustain proliferative signalling, to resist growth regulators and evade growth suppressors, 
they gain replicative immortality and resist cell death, and the whole culminates in cancer 
cells hyperproliferation. Further, to sustain this growth rate and the subsequent needs in 
nutrients and oxygen supply, cancer cells trigger continuous angiogenesis (angiogenic 
switch) leading to their characteristic anarchic vasculature. Lastly, malignancies gain invasive 
and migratory abilities following the loss of cell-cell and cell-ECM junctions or 
overexpression of pro-EMT transcription factors.  
Moreover, recent knowledge permitted to index additional “enabling traits” represented by 
genomic instability and inflammation highlighting the contribution of the microenvironment 
to tumor progression (Hanahan and Weinberg 2011). Finally, two emerging hallmark 
capabilities further underline cancer cells ability to evade immune destruction and reprogram 
their metabolism. In this regard, cancer metabolism has gained tremendous interest in the past 
two decades allowing considerable progress in understanding the complexity of malignancies 







Mitochondria: cellular hub for metabolic and bioenergetic reactions  
Far from their bacterial origins, mitochondria constitute important organelles that occupy a 
central role in many cellular processes. Next to cellular respiration, they are also involved in 
programmed cell death, calcium-homeostasis and stress response. As semi-independent 
organelles, mitochondria carry their own genetic material and translation machinery 
contained in the mitochondrial matrix (MM) (Friedman and Nunnari 2014). Mitochondrial 
DNA (mtDNA) is a double stranded circular molecule of 16,569 base pair that encodes for 13 
proteins of the total proteins the organelle counts, the rest being encoded by nuclear DNA 
(nDNA), synthetised in the cytoplasm then imported to the mitochondria. mtDNA displays 
some peculiarities that distinguish it from genomic DNA: in addition to being deprived of 
protective histones or a DNA repair system, mitochondrial DNA is maternally inherited and 
can exist in multiple copies in a single organelle (polyploidy). Hence, a condition of 
homoplasmy (wild-type or mutant) thus exists when all mtDNA copies are identical. By 
opposition, the co-existence of two mitogenomes (wild-type and mutant) in a single cell 
defines a heteroplasmic state. In a general manner, a heteroplasmic mutation translates at the 
phenotypic level beyond a defined threshold (usually between 70-90% mutation load). In 
addition, the homo/heteroplasmy (mutation load) levels is also influenced by mitotic 
segregation as mitochondria and thus mtDNA molecules are randomly segregated during 
mitosis.  
The countenance of the MM is englobed by the inner mitochondrial membrane (IMM), 
known for its highly restricted permeability. A second, more permeable membrane wraps up 
the inner mitochondrial membrane thereby creating a space in between: the intermembrane 
mitochondrial space (IMS) (Frey and Mannella 2000). The IMM forms invaginations or 
“cristae” within the mitochondrial matrix which density directly reflects tissue energetic 
needs. At the functional level, mitochondria are important players involved in a plethora of 
reactions both in cellular bioenergetic and metabolism. Following glycolysis-derived 
pyruvate conversion to Acetyl Co-A (Ac-CoA) in the mitochondrial matrix, the latter is 
coupled to oxaloacetate and engages in the tricarboxylic acids (TCA) cycle reactions. Deeply 
anchored into the inner mitochondrial membrane IMM, reside the respiratory chain 
complexes or electron transport chain (ETC) (Khulbrandt et al., 2015). From complex I to 
complex IV, the enzymatic giants insure oxidative phosphorylation of reducing equivalents 
(NADH, FADH2) produced by the TCA cycle, electron transport and proton pumping to the 
IMS space thus creating an electrochemical gradient necessary for ATP synthesis by F0 F1-
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ATP-synthase or complex V that together with other 4 complexes of ETC formed the 
oxidative phosphorylation (OXPHOS). Besides glucose metabolism, mitochondria are at the 
heart of many other catabolic processes (Fatty acids β-oxidation, glutamine and branched-
amino acids) as well as biosynthetic reactions including nucleotides, amino acids, fatty acids 
and heme synthesis. Finally, the organelles are also indispensable for metabolic by-products 
elimination (urea cycle, ROS) (Spinelli and Haigis 2018).  
Mitochondria and metabolic reprogramming in cancer  
Because of their central position in cellular metabolism and energy production, since the mid-
90s mitochondria have gained growing interest for their contribution to key steps of 
tumorigenesis (initiation, progression and metastasis). Indeed, numerous studies demonstrate 
the active implication of the organelles as modulators of metabolic and hypoxic adaptations 
characterising cancer cells thereby sustaining their uncontrolled proliferation and growth into 
tumors (Porporato et al., 2018).  
In cancer cells, glycolysis and TCA cycle intermediates are deviated from their initial 
purposes. Instead of energy production, they are mainly used to provide the necessary 
precursors for biosynthesis of macromolecules (proteins, lipids, nucleic acids) in order to 
support proliferation. In this frame, Otto Warburg was the first to note that cancer cells 
preferably use glucose as an energy source to release lactate thereby concluding to a possible 
mitochondrial aberration. Later, further studies demonstrated that cancer cells rewire their 
metabolism from oxidative to glycolytic independently from their mitochondrial efficiency 
(Smolková et al., 2011). Indeed, despite the low energy yield glycolysis allows (2 ATP 
molecules vs. 36 from oxidative phosphorylation), it seems to rather constitute a more 
favourable alternative for fastly proliferating cancer cells (Lunt and Vander Heiden 2011). In 
this regard, glucose being the most abundant nutrient in the extracellular space, cancer cells 
augment their glucose consumption rate by upregulating the expression of glucose 
transporters and glycolytic enzymes as a result of oncogenes-mediated stimulation 
(DeBerardinis et al., 2008) (Lunt and Vander Heiden 2011). Another advantage of the 
glycolytic pathway is that it provides cancer cells with the precursors necessary for 
macromolecules biosynthesis such as pyruvate and citrate for de novo lipid synthesis, 




On the other hand, glutamine is the most abundant amino acid available to cancer cells. It 
therefore plays an important role in carbon and nitrogen metabolism. In this frame, 
glutaminolysis constitutes an anaplerotic pathway that refills the TCA cycle with α-
ketoglutarate (αKG). In fast proliferating cells, it constitutes a new entry point to the cycle as 
a result of glucose shifting from oxidative phosphorylation (DeBerardinis et al., 2007). 
Moreover, several studies demonstrate that glutamine-derived αKG, undergo mitochondrial 
reductive carboxylation as the main carbon source to support the growth of cancer cells 
bearing mitochondrial defects  or submitted to low oxygen conditions (Fendt et al. 2013) 
(Mullen et al., 2012) (Wise et al., 2011) (Metallo et al., 2012). The ketoacid is converted to 
citrate through an isocitrate dehydrogenases IDH1/IDH2-dependent reaction (Wise et al., 
2011) (Metallo et al., 2012). Part of the citrate generated is used to sustain lipogenesis 
through Ac-CoA, on the one hand, and to replenish the pool of TCA cycle with oxaloacetate 
(OAA) and other intermediates. Paradoxically, a portion of the glutamine-derived αKG still 
engages in the oxidative TCA cycle pathway in order to generate reducing equivalents 
(Mullen et al., 2014). Therefore, even though the main energy sources are rearranged in 
cancer cells, it is now clear that the co-existence of both glycolytic and oxidative/reductive 
metabolisms all of which are complimentary to sustain cancer cells high growth rate (Zheng 
et al., 2012).  
HIFs signalling and hypoxic adaptation in cancer  
Hypoxia Inducible Factors (HIFs) are heterodimeric transcription factors of the basic-helix-
loop-helix-PER-ARNT-SIM (bHLH-PAS) family (Wang et al., 1995). At the structural level, 
the transcription factors include a constitutively expressed nuclear-subunit β (Aryl 
Hydrocarbon Receptor nuclear translocator, ARNT) and an oxygen-labile subunit α which 
expression is tightly regulated by oxygen availability. In mammals, subunit β counts two 
described isoforms, respectively ARNT (or HIF-1β) and ARNT2, while three paralogues of 
the α subunit have been described so far, HIF-1α, HIF-2α and HIF-3α. HIF-1α and HIF-2α 
are the best characterised and structurally similar. HIF-3α presents distinct structural features 
(Yang et al., 2015) (Figure 1) and can exist as different spliced variants some of which were 
reported to negatively regulate HIF-1α and HIF-2α activity (Makino et al., 2001). In addition 
to their bHLHL and PAS domains, HIFs structures encompass N- and C-transactivation 
domains (N-TAD, C-TAD). In addition, subunits alpha specifically harbours an overlapping 
oxygen-dependent degradation domain (ODDD) (Figure 1). HIF-1α is ubiquitously expressed 
in mammalian cells whereas HIF-2α and HIF-3α expression is selectively restricted to some 
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tissues (Ema et al., 1997) (Yang et al., 2015). HIF-1α paralogs were also identified in other 
lower organisms, for instance in C. elegans as well as in Drosophila Similar is the 
corresponding paralogue thus suggesting the conservation of HIF system in all organisms 
(Semenza 2012).   
 Under low oxygen tension (0.1-5% O2), subunits α escape oxygen-dependent degradation, 
translocate to the nucleus where their heterodimerization with subunit β occurs through a 
complex interaction involving the proteins respective bHLH and PAS-A domains (Jiang et 
al., 1996). The complex formation allows further interaction with a core DNA sequence 
(G/ACGTG) located in the Hypoxia Response Element (HRE) in the promoter region of HIF 
target genes, thereby triggering their transcription. Conversely, in high oxygen tension (5-
21% O2) subunits α are rapidly degraded (half-life <5minutes) through a complex oxygen-
dependent enzymatic cascade. HIF sensing is mediated by post-translational modifications at 
the level of two proline residues located within the ODDD of subunits α (Figure 1). Prolines 
402 and Pro564 for HIF-1α or Pro405 and Pro531 for HIF-2α undergo a 4-trans-
hydroxylation catalysed by Fe(II)/αKG-dependent dioxygenases (αKGDDs), namely prolyl 
hydroxylases containing domain (PHDs) (Jaakkola et al., 2001) (Ivan et al., 2001). As 
members of the αKGDDs family, the activity of the dioxygenases is allosterically regulated 
by the levels of TCA cycle intermediate α-ketoglutarate (αKG). Conversely, HIF-3α 
possesses one single proline hydroxylation site in its ODDD. This step is necessary for 
further recognition and binding by von Hippel-Lindau (pVHL) tumor suppressor protein of 
the E3 ubiquin ligase complex (Yu et al., 2001). HIF α subunits are subsequently 
polyubiquitinated and targeted to proteasomal degradation. HIF signalling is further 
controlled by another post-translational modification catalysed by a distinct enzyme of the 
αKGDDs family, namely Factor Inhibiting HIF (FIH1) which interferes with its 
transcriptional activity. In this regard, FIH1 catalyses a β-hydroxylation of an asparagine 
(Asn) residue located in the hypoxia protein C-TAD domain (Asn803 for HIF-1α and Asn851 
for HIF-2α) thereby impeding its interaction and subsequent binding to cysteine/histidine-rich 
domain (CH1) domain of p300/CBP transcriptional co-activator (Mahon et al., 2001) (Lando 
2002) (McNeill et al., 2002) (Figure 1). This mechanism thus constitutes an additional O2-
dependent checkpoint to control HIF pathway. Next to the canonical oxygen-dependent 
regulation, HIF-1α stability, transcriptional and translational expression can be modulated by 
different effectors following non-canonical mechanisms especially in the context of cancer 
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(Iommarini et al., 2017). Amongst these non-canonical effectors are oncometabolites, which 
will be described in detail in the next section. 
 
 
Figure 1: Schematic representation of HIFs structural domains and their corresponding 
roles (Ravenna et al., 2015). Each motif is represented in a different colour. All HIF 
isoforms bear a basic-Helix-Loop-Helix (bHLH) and a tandem PER-ARNT-SIM (PAS-A, 
PAS-B) domain necessary for DNA binding and subunits heterodimerization, respectively. 
HIF α subunits harbour an N-Transactivation Domain (NTAD) located within the oxygen-
dependent-degradation domain (ODDD). This latter is site for oxygen-dependent post-
translational hydroxylation of two proline residues (for HIF-1α and HIF-2α) by prolyl 
hydroxylases ultimately targeting the subunits for proteasomal degradation. By contrast, HIF-
3α includes a single proline residue for hydroxylation. HIF-1α and HIF-2α structures also 
comprise a C-transactivation domain (CTAD) determining for the protein transcriptional 
activity. In this domain resides an asparagine residue site for FIH1-catalysed hydroxylation. 
Instead, HIF-3α possesses a Leucine-zipper domain (LZIP) involved in protein-protein 
interaction. Oxygen-insensitive HIF β subunits are deprived of ODDD and bear a single 
CTAD. P: Proline residue, N: Asparagine residue. Permission to reuse allowed  
 
As described earlier, cancer cells preferably rewire their metabolism towards aerobic 
glycolysis even in high oxygen conditions.  However, tumor organisation due to uncontrolled 
growth and microenvironment pressure all result in chronic HIF signalling especially in the 
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tumors innermost parts. HIF activation orchestrates cell adaptation to low oxygen availability 
in order to sustain cell survival in such extreme conditions.  In this frame, the transcription 
factor counts amongst its numerous targets many pro-glycolytic genes. It mediates an 
increase in glucose consumption rates by upregulating glucose transporters GLUT1, GLUT3 
(Semenza et al., 2012). Similarly, it stimulates the expression of different glycolytic enzymes 
including hexokinases 1 and 2 (HK1, HK2), phosphofructokinase (PFK1, PFK2), aldolase A 
and C (ALDA, ALDC), Pyruvate Kinase M2 (PKM2). Pyruvate dehydrogenase kinases 
(PDK1, PDK3) (Kim et al., 2006) are also upregulated by hypoxia resulting in pyruvate 
dehydrogenase (PDH) inactivation thereby opposing to pyruvate engaging into the TCA 
cycle and favouring its conversion to lactate. Consequently, lactate dehydrogenase A 
(LDHA) as well as mono-lactate transporters (MCT1, MCT4) expression is upregulated in 
hypoxia along with carbonic anhydrase (CA9). The latter enzyme contributes in concert with 
MCT transporters to insure H+ efflux thereby inducing intracellular alkalinisation and 
extracellular acidification reported to promote invasion (Figure 2) (Semenza et al., 2012). In 
line with this, HIF stimulates the expression of metallo-proteinases (MMP-2, -9, -14) and 
extracellular matrix remodelling further enhancing cancer cells metastatic potential (Semenza 
et al., 2012). As an adaptative factor for oxygen restriction, HIFs stimulates angiogenesis 
through the increased transcription of angiogenic growth factors including VEGF to enhance 
vessel formation thereby sustaining one of cancer hallmarks (Figure 2) (Semenza et al., 
2012). Further, hypoxia was reported to downregulate oxygen consumption along with ETC 
activity (Papandreou et al., 2006) (Masson and Ratcliffe 2014) while promoting the 
expression of glutamine dehydrogenase (GDH) likely to stimulate glutamine-dependent 
anaplerosis (Jiang et al., 2017). In these conditions glutamine reductive carboxylation is 
preferably used by cancer cells to sustain fatty acid and lipids synthesis as a consequence of 
pyruvate rewiring from the mitochondria (Wise et al., 2011) (Metallo et al. 2012). Finally, by 
eliciting the activation of repressor genes SNAI1, SNAI2, ZEB1, ZEB2, HIF is also involved 
in epithelial-to-mesenchymal transition (EMT) (Unwith et al., 2015) (Semenza et al., 2012) 
and regulates several genes involved in stemness, cell immortalisation, genomic instability 




Figure 2: HIF signalling and cancer hallmarks: beyond metabolic adaptation (Wigerup 
et al., 2016). Through a wide range of targets, the activation of chronic hypoxic signalling 
promotes multiple processes that ultimately contribute to sustain cancer progression, 
metastasis and resistance to therapy. Permission to reuse allowed 
 
Oncometabolites contribution to cancer progression  
Succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenases 
(IDH1 and IDH2) are considered as tumor suppressors since loss of function mutations 
affecting these TCA cycle enzymes were reported in different types of cancers. The 
subsequent accumulation of substrate metabolites, namely succinate (SA), fumarate (FA) and 
2-hydroxyglutrate (2-HG) was demonstrated to play an active role in oncogenic signaling, 
thereby classifying them as oncometabolites (Sciacovelli and Frezza 2016). Loss of function 
mutations in SDH genes have been reported in hereditary paraganglioma and 
pheochromocytoma, renal cell carcinoma, gastrointestinal stromal tumors and T-cell 
leukemia (Niemann and Müller, 2000) (Vanharanta et al., 2004) (Stratakis et al., 2009) 
(Baysal et al., 2007). On the other hand, FH was found mutated in hereditary leyomatosis and 
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renal cell carcinoma, paraganglioma and pheochromocytoma, clear cell carcinoma and 
neuroblastoma (Tomlinson et al., 2002) (Castro-Vega et al., 2014), whereas heterozygous 
somatic mutations affecting IDH1 and IDH2 were reported in gliomas and acute myeloide 
leukemias (AML) (Yan et al., 2009)(Mardis et al., 2009). In the latter case, the resulting 
arginine replacement (R132 in IDH1 and R172 or 140 in IDH2), provokes a shift in the 
enzyme’s substrate affinity (Yang et al., 2010) and the gain of an NADPH-dependent 
neomorphic function leading to αKG reduction to (R)-2-hydrxyglutarate (D-2-HG) (Dang et 
al., 2009) (Ward et al., 2010). Notably, 2-HG generation by wild-type IDH2 was also 
reported during glutamine reductive carboxylation in cancer cells submitted to hypoxia (<1% 
O2) (Wise et al., 2011). Since 2-HG is a chiral molecule, the existence of an L-2-HG isomer 
has also been reported in human cancer cells bearing defects in mitochondrial respiratory 
chain (Mullen et al., 2012) or as a result of promiscuous activity of LDHA and malate 
dehydrogenase (MDH) under hypoxic conditions (Intlekofer et al., 2015) (Intlekofer et al., 
2017). At the structural level, SA, FA, D-2-HG and L-2-HG are very close to αKG. Such 
structure analogy allows oncometabolites to competitively inhibit the activity of αKG-
dependent dioxygenases by occupying the enzyme’s catalytic site, with different levels of 
potency (Koivunen et al., 2007) (Xu et al., 2011). As members of the αKG-dependent 
dioxygenases family (αKGDDs), PHDs and FIH1 constitute privileged targets for the 
oncometabolites. In this regard, inhibition of PHDs following SA and FA accumulation was 
shown to block HIF-1α degradation in normal oxygen conditions, thereby inducing a state of 
pseudohypoxia in vitro and in vivo cancer models (Pollard et al., 2005) (Selak et al., 2005) 
(Isaacs et al. 2005). Although their effect on PHDs is still debated, both D- and L-2-HG 
markedly reduced FIH-dependent hydroxylation of HIF-1α, explaining in part the high levels 
of the hypoxia protein observed in IDH-mutated cancers (Zhao et al., 2009) (Chowdhury et 
al., 2011).  
Genetic instability is a hallmark of cancer (Hanahan and Weinberg 2011). In line with this, 
epigenetic aberrations have also been widely described in cancers (Esteller et al., 2008). They 
are even thought to precede classical transforming events as in the case of tumor suppressors 
genes. Indeed, cancer cells show genome wide hypomethylation, CpG islands promoter 
hypermethylation, as well as histone modification, all converging to genomic instability 
(Esteller et al., 2008). The dynamic character of epigenetic modifications and the tight 
interplay with cellular metabolism altogether play a part in malignant transformation. In this 
regard, the implication of oncometabolites in the modulation of this aspect has been widely 
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studied, most likely by altering the activity of Ten Eleven Translocases (TETs) family of 
DNA 5-methylcytosine hydroxylases and Histone Lysine demethylases (KDMs) both 
members of the αKGDDs superfamily. In this frame, several studies linked supra-
physiological levels of SA, FA or 2-HG with repressed activity of TET hydroxylases  and 
KDMs in various cancer subtypes (Xiao et al., 2012) (Xu et al., 2011) (Shim et al., 2014) 
(Laukka et al., 2016) (Chowdhury et al., 2011). A further illustration of this detrimental effect 
was the hypermethylated phenotype displayed by SDH and FH-deficient tumors (Letouzé et 
al., 2013) (Loriot et al., 2015) (Sciacovelli et al., 2016) as well as in IDH-mutated models 
(Figueroa et al., 2010) (Turcan et al., 2012) (Xu et al., 2011). Accordingly, pathological 
levels of SA, FA and 2-HG promoted EMT activation in cancer cell models (Loriot et al., 
2015) (Sciacovelli et al., 2016) (Grassian et al., 2012) (Colvin et al., 2016) strongly 
confirming their pro-tumorigenic activity. In particular, 2-HG was also reported to block cell 
differentiation in hematopoietic cells (Figueroa et al., 2010) (Losman et al., 2013) (Lu et al., 
2012), thereby supporting the pro-leukemogenic role of this oncometabolite.  
 
However, the inhibition exerted by oncometabolites on αKGDDs family members was shown 
to be reversible considering its competitive nature. This can be achieved by modulating 
αKG/oncometabolite ratio through αKG supplementation (Xu et al., 2011) (MacKenzie et al., 
2007) (Tennant et al., 2009). 
 
αKG: a metabolite with pleiotropic activity 
αKG at the heart of physiological reactions 
αKG, or 2-oxoglutarate (2OG) is a tricarboxylic acid composed of 5 carbons with two weak 
carboxylic functions and a ketone group in the α position. Within the TCA cycle, IDH3 
produces αKG through an irreversible reaction taking place in the mitochondria and where 
NAD+ is limiting (Plaut et al., 1983). Wild-type IDH1 and IDH2 normally catalyse the 
reversible NADP+-dependent oxidative decarboxylation of isocitrate to either in the cytosol 
(IDH1) or in the mitochondria (IDH2).  As a precursor of glutamine, the ketoacid can also 
originate from glutaminase (GLS)-mediated glutaminolysis and subsequent glutamate 
deamination by glutamate dehydrogenase (GDH) (Figure 3). Conversely, the reaction 
catalysed by GDH being reversible, transamination of αKG by GDH forms glutamate, which 
further amination by glutamine synthase (GS) gives glutamine. Furthermore, an additional 
reaction mediated by cytosolic or mitochondrial ɷ-amidase, particularly reported in 
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mammalian liver and kindey, can also generate αKG as follows: glutamine transamination by 
glutamine transaminase (GT) first produces an intermediate ketoacid: a-ketoglutaramate, 
which subsequent hydrolysis by ɷ-amidase releases αKG and ammonia (Cooper et al., 2016). 
Hence, through the glutamine-αKG axis, the ketoacid is tightly involved in amino acids 
metabolism, an anabolic pathway of particular importance especially in cancer cells (Xiao et 
al., 2016). Likewise, glutamate pyruvate transaminases (GPT1/2) and glutamate oxaloacetate 
transaminases (GOT1/2 cytoplasmic and mitochondrial respectively) respectively produce 
αKG from glutamate and pyruvate or oxaloacetate transamination reactions (Figure 3). 
(Sookoian et al., 2015). Like most of the TCA cycle intermediates, αKG diffuses from the 
mitochondrial matrix to the cytoplasm and vice-versa. It crosses the inner mitochondrial 
membrane through a 2-oxoglutarate-malate antiporter and the outer mitochondrial membrane 
through voltage-dependant anion channel (VDAC) (Monné et al., 2013).  
Owing to its metabolic origin and structure, αKG is found at the centre of a wide range of 
physiological processes qualifying it as pleiotropic molecule (Abla et al., 2020). First of all, 
both glutamine and αKG have an anabolic role on protein synthesis since glutaminolysis 
increases intracellular glutamate pools which will be used together with αKG as precursors in 
transamination reactions for proline, arginine, ornithine amino acids synthesis. The two latter 
amino acids are known to stimulate growth factors release such as growth hormone (GH) and 
Insulin-like growth factor (IGF) (Harrison and Pierzynowski, 2008). Clinical studies also 
reported benefits of αKG alone or in combination (with ornithine or arginine) both in animals 
and in humans on protein synthesis, muscle mass and body weight gain in post-operative, -
trauma patients or those suffering from extensive burns, but also in malnourished aging 
patients (Zdzisińska et al., 2017). Further, many studies related positives effects of αKG on 
bone tissue formation suggesting the metabolite to have an anabolic effect and inhibit bone 
resorption in vivo (Zdzisińska et al., 2017). Secondly, αKG structure confers the metabolite a 
high reactivity. Indeed, with its two carboxylic and ketone groups, αKG is capable of 
neutralising hydrogen peroxide (H2O2) through non-enzymatic oxidative decarboxylation 
thus preventing oxidative stress damage in mammalian and Drosphila melanogaster models 
(Long et al., 2011) (Bayliak et al., 2015). αKG was also described to neutralise ammonia and 
ethanol-induced oxidative stress as well as for its antidote effect in case of cyanide poisoning 




Figure 3: αKG biosynthetic pathways (Abla et al., 2020). αKG derives from glutamine and 
glutamate deamination in the mitochondria, mediated by glutaminase (GLS) and glutamate 
dehydrogenase (GDH), respectively. In the cytosol, glutamine transamination by glutamine 
transaminases (GTs), generates α-ketoglutaramate that is subsequently converted into αKG 
by an ω-amidase. Moreover, αKG can originate from transamination of glutamine by GTs or 
glutamate by GPT1/GOT1, in the presence of Pyr/OAA respectively. Inside the 
mitochondria, GPT2 and GOT2 isoforms catalyze the same reactions. Lastly, the conversion 
of TCA cycle intermediate isocitrate catalyzed by isocitrate dehydrogenases IDH2 and IDH3 
in the mitochondria or IDH1 in the cytosol constitutes another source of αKG 
 
The processes of metabolism and aging being tightly related, dietary restrictions and 
pharmacological modulation of energy metabolism were previously described to benefit 
longevity although the underlying molecular mechanisms are still not clearly defined. As 
aging is often coupled to events like genomic instability, telomere shortening, epigenetic 
alterations, through its metabolic properties αKG seems to display a beneficial effect in 
reversing or delaying such alterations. In this frame, Chin and colleagues showed that αKG 
was able to inhibit ATP synthase β-subunit in C. elegans, resulting in increased lifespan and 
autophagy induction through the inhibition of TOR signalling (Chin et al., 2014). In 
continuity with this, the metabolite delivered as calcium salt similarly increased lifespan, 
survival and age-related morbidities reducing different negative factors such as inflammation 
in female mice (Shahmirzadi et al., 2019). Interestingly, αKG was also correlated to 
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pluripotency maintenance in mice embryonic stem cells by promoting histone and DNA 
demethylation (Carey et al., 2015).  
αKG as a limiting substrate for dioxygenases 
In addition to bridging energy and amino acid metabolisms, the ketoacid is at the crossroads 
of biological events orchestrated by the super-family of αKGDDs enzymes. Being the 
dioxygenases obligate substrate, the enzymes use αKG along with iron and ascorbate to 
catalyse hydroxylation reactions on specific residues of their target proteins while releasing 
succinate as in the regulation of HIF levels by PHDs or during the early phases of nucleic 
acids N-demethylation endorsed by TET family enzymes. 
αKGDDs constitute a widespread family of phylogenetically conserved enzymes harbouring 
the same fold and requiring αKG as well as a non-haem iron for their catalytic activity. In 
humans, these enzymes display affinity for various types of substrates ranging from amino 
acid residues, nucleic acids to metabolic intermediates (Markolovic et al., 2015). At the 
structural level, bona fide αKGDDs share the same double-stranded β-helix (DSBH) fold, 
also commun to the Jumonji C (JmjC) chromatin-associated proteins. The DSBH core is 
made of 8 antiparallel β-strands (I–VIII), that fold two by two in a helical manner (β-helix) to 
form two distorted β-sheets conferring to the enzymes a characteristic distorted barrel 
structure at the end of which reside the active site with iron/metal and αKG binding pockets 
(Islam et al., 2018). αKG dioxygenases catalyse a two-electron oxidation hydroxylation 
reaction of their respective substrates through the sequential binding of ferrous iron, αKG 
followed by O2 and substrate. Binding of each respective substrate implies interactions with 
specific amino-acid residues and coordination sites occupied by 6 water molecules (Schofield 
and Ratcliffe 2004). First, iron binding to the active site is enabled by interaction with a 
highly conserved amino-acid triad (facial triad) that constitute the iron Fe(II)-binding motif 
(Figure 4). Facial triad typically presents as a HX(D/E)…H motif and include a proximal and 
a distal histidine residues (respectively located in the β-II and β-VII strands), while the third 
residue was mainly reported to be an aspartate (Hegg and Jr 1997). Then, two coordination 
sites occupied by two water molecules are subsequently displaced to allow αKG binding. The 
ketoacid chelates Fe2+ in a bidentate manner via its C-1 carboxylate and ketone oxygen, 
thereby forming an octahedral complex (Figure 4). Further electrostatic interactions between 
its C-5 carboxylate and a basic residue as well as a neutral side chain residue allow binding 
stabilisation (Markolovic et al., 2015). This step is followed by substrate binding and 
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subsequent uncovering of the final coordination site favouring oxygen binding. αKG 
oxidative decarboxylation produces succinate, carbon dioxide and a water molecule along 
with a ferryl intermediate (FeIV_O) (Figure 4) which reacts with substrate C-H to form the 
hydroxylated product, while Fe(IV) is reduced to Fe(II).  At the term of the reaction, the 
hydroxylated product is first released followed by succinate (Islam et al., 2018). Of note that 
some, but not all αKGDDs also necessitate the presence of ascorbate which seems to mainly 
stand an antioxidant role protecting the iron metal from oxidation.  
 
Figure 4: Mechanism of αKG-dependent dioxygenases catalysed hydroxylation 
(Adapted from (Aik et al., 2012). First, iron binds to the active site following interaction 
with the amino-acids facial triad (1). Then, two coordination sites occupied by two water 
molecules are displaced to allow αKG binding. The ketoacid chelates Fe
2+
 in a bidentate 
manner thereby forming an octahedral complex (2). This step is followed by substrate 
binding (2) and subsequent uncovering of the final coordination site favouring oxygen 
binding (3). αKG oxidative decarboxylation produces succinate, carbon dioxide and a water 
molecule along with a ferryl intermediate (FeIV_O) (4) which reacts with the substrate to 
form the hydroxylated product, while Fe(IV) is reduced to Fe(II) (5). The hydroxylated 
product is first released followed by succinate (5). Permission to reuse allowed 
 
Amongst the αKGDDs super-family, prolyl hydroxylases (PHDs) are the most important and 
the best described members, because of their role in hypoxia sensing. Displaying very high 
affinity for molecular oxygen with Km values in the range of 100-250µM, these enzymes thus 
constitute notable oxygen sensors (Kaelin and Ratcliffe 2008). To date, three PHD paralogues 
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have been described so far: PHD1, PHD2 and PHD3 (also known as EglN2, EglN1 and 
EglN3 respectively, the orthologues of Egl-9 in C. elegans) (Epstein et al., 2001) (Ivan et al., 
2002) although a fourth isoform has also been reported (Kaelin and Ratcliffe 2008). At the 
cellular level, PHD1 was shown to exclusively locate in the nucleus while PHD2 is 
cytoplasmic and PHD3 was found in both sub-cellular compartments (Metzen et al., 2003). In 
addition to oxygen sensing and HIF regulation, some PHDs were reported to be involved in 
additional cellular processes. For instance, PHD1 and PHD3 have been reported to have 
growth suppressive effects (Erez et al., 2003) (Fong and Takeda, 2008). Presenting with the 
lowest Km for O2, studies in mammalian cells have shown that HIF-1α levels are mainly 
regulated by PHD2 in normoxia and PHD1 to a lesser extent (Berra et al., 2003). By contrast, 
PHD1 preferably acts on HIF-2α, while PHD3 displays affinity only for HIF-2α C-TAD 
(Appelhoff et al., 2004) (Ivan and Kaelin 2017). Although altogether, the process of HIF 
regulation seems to be more intricate and mainly dependent on the cellular context as well as 
expression levels of each respective isoform (Ivan and Kaelin 2017). Interestingly, PHD2 and 
PHD3 but not PHD1 expression was described to be stimulated by hypoxia suggesting the 
existence of a negative feedback control on HIF signalling (Berra et al., 2003). FIH1, for 
which a single isoform has been described so far, presents a different sequence to PHDs and 
further structural and computational studies identified the enzyme with a Jumonji homology 
region thereby classifying it in a distinct subfamily of αKGDDs (Hewitson et al., 2002) 
(Lando et al., 2002). FIH1 displays a Km value of 90µM for O2 (Koivunen et al., 2004). 
Likewise, to carry on their catalytic activity, PHDs and FIH1 are strictly dependent on αKG 
intracellular amounts with Km values of 50µM and 25µM, respectively, suggesting the 
enzymes activity can be influenced by the slightest fluctuations in the ketoacid levels (Table 
1) (Koivunen et al., 2004). As a matter of fact, it can also be modulated by the levels αKG of 
structural analogues, namely succinate which constitutes the product of the HIF-
hydroxylating enzymes along with other oncometabolites (FA and 2-HG) (Table 1). In this 
frame, fumarate was described to be the most potent in negatively modulating PHDs 
dioxygenase activity (Koivunen et al., 2007) followed by succinate, thereby giving more 
insights into their role as oncometabolites. Citrate, oxaloacetate and pyruvate also displayed 
the ability to interfere with PHDs and FIH1 with different levels of potency. The latter seems 
to be more sensitive to citrate and oxaloacetate competitive binding (Koivunen et al., 2007). 
It is important to note that the reported values are calculated on recombinant enzymes. Thus, 




Table 1: Km and IC50 values of αKGDDs for their co-substrates and αKG structural 
analogues (Adapted from (Losman et al., 2020). 
 
Eukaryotic chromatin is organised in basic units, namely nucleosomes. Nucleosome structure 
comprises an octamer of core histones (H2A, H2B, H3 and H4) around which is wrapped a 
147 bp DNA segment. Chromatin core histones can undergo numerous post-translational 
modifications (methylation, acetylation, phosphorylation, ubiquitylation and SUMOylation) 
at the level of their free tails. In particular, methylation span at lysine and arginine residues. 
Histone modifications directly reflect the state of chromatin folding (euchromatin vs. 
heterochromatin) hence giving insight on transcriptional activation or repression. Long 
considered as static, histone methylation landscape seems to define a histone code that is read 
and interpreted by adapted proteins (Pedersen and Helin 2010). DNA and histone tails 
epigenetic modifications play and important role in the regulation of transcription regulation, 
genome integrity and cell fate.  
Enzymes of the Ten Elven Translocase family are dioxygenases known to catalyse active 
DNA-demethylation by oxidising 5-methylcytosine (5mC) in CpG rich islands of genes 
promoters (Tahiliani et al., 2009). This process takes place in a multiple step reaction that 
successively gives rise to 5-hydroxymethylcytosine (5-hmC), 5-formylcytosine (5fC) then 5-
carboxylcytosine (5caC) ultimately leading to base-excision by Thymine-DNA glycosylase 
(TDG) (Ito et al., 2011) (He et al., 2011). There are known 3 TET isoforms, TET1-TET3 all 
of which display the typical double-stranded β-helix fold characterising αKGDDs (Wu and 
Zhang 2017). As a member of Fe(II)/αKG-dependent dioxygenases, TETs-catalysed reaction 
on DNA requires the presence of both substrates for optimal activity. Likewise, the activity of 
the enzymes is also sensitive to oxygen availability (Table 1).  
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In parallel, chromatin-associated Jumonji-containing domain proteins (JmjC) represent the 
largest class of demethylases and belong to the αKGDDs family thanks to structural 
similarities with other members of the super-family. These proteins, also known as JmjC 
histone demethylases (JHDM) or Lysine Demethylases (KMDs) thus harbour a JumonjiC 
(JmjC) domain and are capable of catalysing histone demethylation through oxidative 
decarboxylation of αKG in the presence of O2 and Fe(II) (Tsukada et al., 2006). As stated in 
previous sections, both TETs and KDMs are sensitive to competitive inhibition by 
oncometabolite 2-HG (Xu et al., 2011), both 2-HG enantiomers acting as weak competitive 
inhibitors and reversibly occupying the enzymes catalytic site (Laukka et al., 2016) (Xu et al., 
2011). 
Next to its role in oxygen-dependent HIF degradation and epigenetic regulation of gene 
expression, αKG is also involved in the synthesis and crosslinking of collagen fibers, the 
major component of connective tissues (Figure 5). Collagen strains are composed of amino 
acids triplet Xaa-Yaa-Gly, where Xaa is usually (2S)-proline, Yaa, (2S,4R)-hydroxyproline 
and Glycine residues. Collagen fibers are stabilised under the effect of two types of αKG-
dependent dioxygenases: proline 4(R)-hydroxylase (P4H), which catalyse stereospecific trans 
prolyl 4-hydroxylation of the proline residue in the Yaa position (Gorres and Raines 2010), 
and proline 3(S)-hydroxylases which catalyse prolyl-3-hydroxylation, at Xaa position. By its 
chemical properties trans 4-hydroxyproline stabilizes collagen polypeptides. This step is 
necessary for subsequent folding of collagen triple helixes thus setting the pavement to other 
post-translational modifications. Like other OGDDs, P4H requires substrates αKG and O2, 
Fe(II) and ascorbic acid as a cofactor to reduce iron. The lack of ascorbate causes the 
development of scurvy disease secondary to prolyl hydroxylase inactivity and thus collagen 
instability.  
Moreover, αKG pleiotropic position also involves it in L-carnitine biosynthesis thereby in 
lipid metabolism, by serving as a substrate for N-methyllysine hydroxylase (NMLH) and ɤ-
butyrobetain hydroxylase (GBBH). Both enzymes of αKGDDs family respectively catalyse 
the first and last step of L-carnitine synthesis, a cofactor that insures the import of long chain 
fatty acids into the mitochondria for β-oxidation (Vaz and Wanders 2002). On the other hand, 
αKG and PHD1 were reported to modulate NF-κB signalling cascade implicated in 
inflammatory response to cytokines, cell survival and proliferation observed in 
tumorigenesis. Cummins and colleagues (Cummins et al., 2006) demonstrated that 
inactivation of IKKβ kinase following an oxygen-dependent hydroxylation of a proline 
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residue (P191) is mediated by PHD1 (Figure 5). IKKβ is known to activate NF-κB after 
phosphorylating Inhibitory κB-α (IκB-α), thus uncovering the transcription factor’s Nuclear 
Localisation Sequences in hypoxic conditions.  
In conclusion, shedding light on the multiple implications of αKG in all the above-mentioned 
metabolic, epigenetic and regulatory processes gives a general view of multiple virtues the 




Figure 5: Pleiotropic implication of αKG in cell homeostasis (Abla et al., 2020). αKG is 
involved in multiple cellular processes both in physiological and pathological contexts. It 
protects against oxidative stress, modulates protein and lipid biosynthesis, and is involved in 
fatty acids β-oxidation (FAO). As substrate of αKG dependent dioxygenases, it activates 
hydroxylases (PHDs and FIH1) to limit HIF-1α signalling, leading to pVHL-mediated protein 
poly-ubiquitination and proteasomal degradation in normoxia. The metabolite also affects 
gene expression and cell stemness by promoting epigenetic DNA and histone demethylation 
by TETs and KDMs enzymes. Finally, αKG stimulates PHD1 to inactivate NF-κB signalling 
and is likewise determining in the process of collagen monomers stabilization. 
 
Targeting hypoxic adaption as a therapeutic strategy in cancer   
Tumor hypoxia in solid tumors often correlates with a poor prognosis and increased mortality 
in cancer patients (Vaupel et al., 2001) (Bertout et al., 2008). The activation of HIF 
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signalling, or hypoxic adaptation is well documented to confer an aggressive phenotype 
coupled to chemo- and radiotherapy resistance as a result of an uncontrolled tumor growth 
and aberrant vascular architecture (Vaupel et al., 2001) (Bertout et al., 2008). Consequently, a 
great interest had arisen to tackle HIF pathway in neoplasms through direct or indirect 
approaches.  
HIF inhibitors 
One class of compounds developed to target hypoxia signalling are Hypoxia-activated-
prodrugs (HAPs). These inactive compounds engineered to be converted into their active 
pharmacological forms in a hypoxic environment following enzymatic activation present thus 
the advantage of target specificity. Often designed to target DNA replication, many of these 
prodrugs are being presently tested in clinical trials (Phillips et al., 2016). Next to that, a wide 
range of molecules have been reported in literature for their ability to antagonise HIFs 
heterodimerisation, DNA-binding and transcriptional activity or mRNA expression. In this 
frame, acriflavine binds PAS domains of HIF-a1 and HIF-2α subunits and was shown to 
potently reduce tumor growth and vascularization in xenograft models (Lee et al., 2009). 
Similarly, PT2385 which displays a higher affinity for HIF-2α subunit is being investigated 
in clinical trials in patients with ccRCC renal cell carcinomas (Chen et al., 2016). In the class 
of compounds blocking HIF-a transcriptional activity, Bortezomib, a proteasome inhibitor 
already approved for the treatment of multiple myeloma, reportedly stimulated FIH-
dependent repression of HIF-1α transcriptional activity. However, when used as a single 
therapy the drug lacked potency in colorectal cancer patients cohorts (Mackay et al., 2005). 
In the same class, molecules of the chetomin family were not pursued because of toxicity 
issues despite their ability to repress HIF-p300 interaction. In the category of candidates 
opposing to HIF-DNA binding, despite showing interesting effects on VEGF expression in 
vitro, both polyamides and echinomycin were not as potent in clinical trials and were thus not 
pursued. Finally, the largest part of compounds described so far are those blocking HIF 
mRNA translation or protein expression and potentially the most promising. In this scope, an 
interesting candidate is EZN-2698. An RNA antagonist reported for its ability to specifically 
inhibit the expression of HIF-1α mRNA levels and its target genes correlating with reduced 
tumor growth in vitro and in vivo (Greenberger et al., 2008). In clinical trials this compound 
showed promising effects in patients with renal cell carcinoma (Wigerup et al., 2016). Within 
the class of topoisomerase inhibitors, camptothecin analogue, namely topotecan was able to 
downmodulate HIF-1α translation and protein levels resulting in reduced tumor growth in 
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xenograft models (Rapisarda et al., 2009). Further, irinotecan as well as its active metabolite 
(SN38) displayed low toxicity levels and encouraging results in Phase I clinical trials in 
patients with brain tumors (Norris et al., 2014). In addition, compounds opposing to HIF 
stabilisation which have been approved or are currently investigated in clinical studies, 
include histone deacetylase (HDAC) inhibitors (Romidepsin and trichostatin) as well as Heat-
shock protein 90 (Hsp90) inhibitors (Masoud and Li, 2015). In the frame of an indirect 
approach, drugs targeting signalling pathways upstream of HIF are also under investigation. 
Indeed, it is well known that HIF-1α mRNA levels are upregulated by PI3K/AKT/mTOR 
pathway, hence molecules modulating with this pathway can constitute an interesting 
alternative. Amongst mTOR inhibitors, Temsirolimus stands out as the most promising as it 
passed phase II clinical trial and is now approved by the FDA for the treatment of metastatic 
renal cell carcinoma (Revaud et al., 2010) (Batelli and Cho, 2011). 
Although considerable efforts have been invested in developing HIF-targeted therapies, the 
high rate of therapy resistance hints to the necessity of combining approaches in order to 
enhance treatment success chances. In this frame, it is important to note that the severe 
alteration of mitochondrial CI activity has been correlated to chronic HIF-1α destabilisation 
subsequently blocking tumor growth in vitro and in vivo (Kurelac et al., 2019).  
Targeting mitochondrial CI in cancer  
Respiratory complex I (CI) or NADH:ubiquinone oxidoreductase is the largest protein of the 
ETC with its 44 subunits, 7 of which (ND1-6 and ND4L) are encoded by mtDNA. The 
remaining 37 subunits are encoded by nDNA then imported into the mitochondria where they 
assemble into a functional enzyme. This finely tuned process involves different chaperone 
proteins (Guerrero Castillo et al., 2017). Mitochondrial CI plays a key role in energy 
homeostasis and is similarly involved in the maintenance of redox balance as well as in 
cellular processes like apoptosis. The protein heads the ETC to catalyse the oxidation of TCA 
cycle-derived NADH thereby transferring 2 electrons to ubiquinone while pumping two 
protons into the mitochondrial intermembrane space thereby generating an electrochemical 
gradient and contributing to the ATP production by F0-F1 ATP-synthase.   
Despite the great deal of studies reporting mitochondrial mutations spanning in CI subunits in 
many cancers, such mutations are unlikely able to trigger oncogenic transformation per se. 
Nonetheless, the contribution of the mtDNA mutations in CI genes in the process of 
oncogenesis, cancer progression, metastasis and therapy resistance has been widely debated 
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(Leone et al. 2018), and lately further investigations allowed to stratify the pathogenicity of 
such defects depending on: i. the mutation type, ii. the mutation load or threshold (Giuseppe 
Gasparre et al. 2011) (Iommarini et al. 2014) and iii. the functional vs. structural severity 
these mutations induce on the activity of the complex. Consequently, mutations affecting 
mtDNA-encoded subunits are sub-divided in 3 groups: those mildly affecting CI 
function/activity, severe shifts altering the enzyme activity but not its overall stability and 
finally disruptive mutations which totally impair the complex assembly (Iommarini et al. 
2013). 
To further illustrate this concept, heteroplasmic missense or frameshift mutations in mtDNA 
genes encoding for CI subunits were reported to play a pro-tumorigenic role. Consistent with 
a mild functional alteration of the complex enzymatic activity, such mutations were shown to 
enhance cancer cells tumorigenic potential in vitro through mechanisms involving reactive 
oxygen species (ROS), HIF-1a or Akt kinase signallings (Leone et al. 2018). In the same 
time, growing evidence is emerging to support the contribution of mitochondrial mutations in 
CI encoding genes in metastasis and resistance to chemotherapy (Ishikawa et al. 2008) 
(Girolimetti et al. 2017) (Guerra et al. 2012).  By contrast, at homoplasmic loads some 
mutations in CI mtDNA-encoded genes correlated with a reduced tumor growth in vitro and 
in vivo (Park et al. 2009), while studies on indolent oncocytomas carried by our group and 
others unveiled the high occurrence rate of mutations affecting CI genes in this tumor subtype 
(Gasparre et al. 2007). Further modulation of the hetero/homoplasmy levels highlighted the 
oncojanus role of mitochondrial-encoded complex I genes in affecting tumor fate, either by 
impinging tumor progression or on the contrary favouring it. One good example is 
homoplasmic 3571insC/MT-ND1, defined as a disruptive or disassembling mutation as it 
impeaches CI assembly. A homoplasmic but not heteroplasmic load of the mutation, 
translated at a metabolic level with imbalanced αKG over SA ratio in favour of αKG, a 
feature that was similarly recapitulated by genetically CI-deprived cells (Kurelac et al., 
2019). The two metabolites tightly regulating the activity of prolyl hydroxylases and HIF 
sensing, such a metabolic context resulted in chronic HIF-1α destabilisation   ultimately 
blocking tumor growth both in vitro and in vivo (Porcelli et al., 2010) (Calabrese et al., 2013) 
(Iommarini et al., 2014) (Kurelac et al., 2019). 
 
Hence, this knowledge gives further insight into the double-edged implication of 
mitochondrial CI in tumor progression, metastasis and resistance to therapy modulated by the 
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oncojanus role of mtDNA-encoded genes progression. Although further investigation is 
warranted, evidence is also emerging in favour of an oncojnaus implication of CI nDNA-
encoded genes (Leone et al., 2018). 
 
In continuity with this, pharmacological targeting of the complex activity could thus 
constitute an appealing approach for the development of new cancer therapies. In this frame, 
molecules have been reported thus far. Although classical compounds (alkaloids, rotenone, 
piericidin A and capsaicin) displayed strong anti-proliferative properties in vitro, their effect 
is coupled to considerable ROS generation thereby compromising their use for safety issues. 
Many other molecules are emerging and gaining substantial interest. Amongst these, BAY 
87-2243 and AG311 were described to block CI activity leading to reduced oxygen 
consumption and induce cancer cell death in vitro and in vivo in glucose-deprived conditions 
(Bastian et al., 2017). In particular, treatment with BAY87-2243 induced ROS accumulation, 
reduced ATP levels which correlated with AMPK activation in melanoma cells (Ellinghaus et 
al., 2013) (Schockel et al., 2015). More recently, biguanides, drugs approved for the 
treatment of type II diabetes mellitus have gained growing attention for their ability to inhibit 
mitochondrial CI through a non-competitive inhibition of ubiquinone reduction (Bridges 
2014). From this class, a number of studies have been dedicated to studying the anti-
neoplastic effect of metformin, especially after epidemiological studies revealed the drug to 
have protective properties on cancer onset and to ameliorate prognosis. in vitro the drug was 
reported to display an anti-proliferative effect through a specific inhibition of CI. In this 
context, metformin determined a bioenergetic crisis, reduced glucose oxidation in the 
mitochondria and increased cancer cells dependency on glutamine reductive carboxylation 
(Fendt et al., 2013). Like other CI inhibitors, metformin’s anti-neoplastic effect was more 
marked under glucose starvation conditions, suggesting that cancer cells mainly use 
glycolysis for survival following CI inhibition (Birsoy et al., 2014) (Andrzejewski et al., 
2014). Similarly, in our cell models we confirm metformin’s ability to block HIF-1α 
stabilisation (unpublished data) and its capacity to alter cancer cells viability and in vitro 
clonogenic abilities. However, this effect seems to be partly independent from CI activity 
inhibition (off-target effect) and is more important as treatment doses increase. Remarkably, 
metformin, BAY87-2243 and AG311 were all able to induce HIF-1α destabilisation in 
hypoxic conditions in the tested models (Wheaton et al., 2014)  (Ellinghaus et al., 2013) 
(Schockel et al., 2015). A direct consequence of CI inhibitors effect could be a stimulated 
activity of prolyl hydroxylases. Indeed, it is possible that reduced oxygen consumption would 
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increase oxygen availability thereby stimulating prolyl hydroxylases to target HIF-1α for 
degradation even in low oxygen condition (pseudonormoxia). On the other hand, and as 
previously demonstrated in our CI-deprived models, NADH accumulation following the 
abolition of CI-dependent NADH dehydrogenase activity induces an imbalanced 
NAD+/NADH ratio that downmodulates the activity of αKG dehydrogenase complex 
(αKGDHC) causing αKG levels to increase ultimately boosting PHD activity (Calabrese et 
al., 2013) (Iommarini et al., 2014) (Kurelac et al., 2019). Other molecules interfering with the 
complex activity include antidiabetic canagliflozin which was able to inhibit the proliferation 
of prostate and lung cancer cells, reduced glucose uptake and ATP levels leading to AMPK 
phosphorylation (Villani et al., 2016). Similarly, antilipemic agent fenofibrate also showed 
the potency to reversibly inhibit the mitochondrial complex thereby inducing cancer cells 
apoptotic cell death in vitro or autophagy as a mechanism to sustain proliferation (Brunmair 
et al., 2004). The list of CI inhibitors still goes on with compounds from the isoflavonoids 
family (ME-344) or JCI-20679 all of which were reported for their repressive potential on the 
complex activity and on cancer cell growth (Lim et al., 2015) (Akatsuka et al., 2016). 
However, before future therapeutic applications on clinical patients, the mechanism and 
specificity of action as well as safety of each respective candidate still need to be clearly 
assessed.  
αKG as an anticancer agent 
In light of in vitro affinity studies on different αKGDDs (Koivunen et al., 2007), further 
studies demonstrated the reversible nature of αKGDDs inhibition exerted by αKG analogues 
highlighting the importance of the ratio oncometabolite/αKG in such a context. As first 
demonstrated by MacKenzie and colleagues, concomitant increase of αKG levels was able to 
overcome PHD inhibition mediated by SA and FA in an in vitro assay (MacKenzie et al., 
2007). Likewise, 2-HG inhibition of histone demethylases, was also reversed by increasing 
amounts of αKG (Xu et al., 2011). 
This knowledge opened new perspectives for novel therapeutic strategies, amongst which the 
possibility of using αKG as an anticancer agent to counteract oncogenic progression has 
emerged. About a decade ago, the first studies started investigating the ability of αKG to 
oppose to HIF signalling in cancer models, through a provoked intracellular accumulation of 
the metabolite via a genetic or pharmacologic modulation. In this frame, numerous studies set 
the tone, describing antitumorigenic effects of the ketoacid. Our group demonstrated that the 
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increased αKG/succinate and NADH/NAD+ ratio in cells lacking a functional mitochondrial 
complex I. Overall, this condition prevented HIF-1α stabilisation and delayed tumor growth 
both in vitro and in vivo (Porcelli et al., 2010) (Calabrese et al., 2013) (Iommarini et al., 
2014) (Kurelac et al., 2019). We demonstrated that αKG intracellular accumulation is able to 
enhance PHDs activity resulting in chronic HIF degradation even under low oxygen tension, 
a condition we termed pseudonormoxia. By contrast, other works used exogenous 
supplementation of free or conjugated αKG. Indeed, because the hydrophilic character of the 
molecule limits its membrane permeability, some groups opted for cell-permeable αKG ester 
analogues. Such compounds were shown to efficiently permeate through the plasma 
membrane thereby enhancing the metabolite intracellular levels to finally reverse PHD 
inhibition exerted by fumarate and succinate in SDH-deficient cells (MacKenzie et al., 2007) 
(Tennant et al., 2009). Similarly, treating Hep3B and LLC cancer cells models with 
exogenous αKG induced a dose-dependent HIF-1α destabilisation in hypoxia (Matsumoto et 
al., 2006) (Matsumoto et al., 2009) and counterbalanced HIF-1α-nuclear accumulation in 
SDH-mutant fibroblasts (Brière et al. 2005). Further, HIF-1α targeting for proteasomal 
degradation subsequently to αKG-analogues exposure was mediated by PHD2 reactivation 
and independently of oxygen tension in vitro and in vivo (Tennant et al., 2009) (Tseng et al., 
2018) further confirming the role of this isoform in HIF-1α regulation. In continuity with this, 
αKG supplementation correlated with a dose-dependent downregulation of HIF downstream 
targets at transcriptional and post-transcriptional levels (Matsumoto et al. ,2006) (Matsumoto 
et al., 2009) likely suggesting the ketocid also stimulates FIH1 activity. At the metabolic 
level, αKG severely reduced ATP levels, glucose consumption and lactate levels, finally 
leading to a PHD3-dependent apoptotic cell death (Tennant et al., 2009) (Tennant and 
Gottlieb, 2010). Moreover, in combination with respiratory chain complex I inhibitor BAY-
87 2243, dimethyl-αKG was able to block glycolysis through an MDM2-dependent 
transcriptional reprogramming ultimately triggering parthanatos in cancer cells (Sica et al., 
2019). In a metastatic breast cancer cell model αKG-based treatment enhanced oxidative 
phosphorylation, impaired cancer cell clonogenic properties in vitro and tumor growth in vivo 
(Tseng et al., 2018). Interestingly, Rzeski and colleagues reported an anti-proliferative effect 
of αKG on a set of colon adenocarcinomas cells in normoxia (Rzeski et al., 2012). The effect 
was mediated via a blockade in DNA synthesis followed by cell cycle arrest. These reports 
infer multiple implication of the metabolite in distinct signalling pathways that overall 
converge towards a single outcome that is reduced proliferation. Notably, following αKG-
analogues structure optimisation, the ketoacid was able to permeate within complex 3D 
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structures and exhibited a high potency in blocking hypoxic signalling in colon cancer-
derived tumor spheroids (Tennant et al., 2009) while tumor xenografts exposed to those 
analogues were significantly smaller in size and less dependent on glucose consumption 
(Tennant et al., 2009). Intriguingly, despite the block in tumor growth secondary to CI 
ablation, we showed that our CI-deficient models are able to recruit pro-tumorigenic M2 
macrophages in what seems to constitute an adaptative mechanisms aiming to maintain tumor 
subsistence (Kurelac et al., 2019). Of note that αKG was previously reported to favour M2 
macrophages polarisation (Liu et al., 2017), however in our case further investigations are 
necessary to determine if αKG accumulated secondary to CI ablation may result in M2 
macrophages activation as a side-effect. 
More recently, a bulk of studies rather highlighted the implication of αKG in the epigenetic 
regulation of gene expression by modulating histone and DNA demethylation, considering its 
role as a limiting substrate during TETs and KDMs catalysed reactions. In this frame, 
pharmacological or genetic inactivation of a-ketoglutarate dehydrogenase (αKGDH) induced 
an accumulation of intracellular αKG and translated with increased TET1 and TET3 
enzymatic activity both in vitro and in vivo. Such an approach reversed DNA 
hypermethylation and reactivated miR-200 family pathway thereby blocking cell migration 
and EMT in breast cancer models (Atlante et al., 2016). To further emphasize the beneficial 
effect of the metabolite in opposing to the accumulation of repressive epigenetic markers, 
treatment with αKG counterbalanced succinate-mediated inhibition of TETs by increasing 5-
hmC and reducing 5-mC in paraganglioma SDH-deficient cells (Letouzé et al., 2013). 
Moreover, in a pancreas ductal adenocarcinoma (PDAC) model, dimethyl-αKG 
administration reactivated TET-mediated DNA demethylation favouring tumor cell 
differentiation through a mechanism that recapitulates p53 anti-tumorigenic response (Morris 
et al., 2019), while it was shown to counteract Wnt hyperactivation in patients-derived 
intestinal organoid model (Tran et al., 2020). In addition to stimulating histone demethylation 
in breast cancer cells, dimethyl-αKG induced senescence and reversed resistance to genotoxic 





























Solid tumors sustain their high growth rate through a metabolic and hypoxic adaptation 
mainly orchestrated by HIF-1α, which controls the transcription of target genes implicated in 
glycolysis, neoangiogenesis and metastasis. At the clinical level, these tumors are associated 
with a higher risk of therapy resistance, relapse and poor prognosis in cancer patients even 
more that few molecules directly targeting hypoxia/HIF-1α axis have been approved so far 
due to safety issues or limited therapeutic efficacy. We previously showed the lack of 
respiratory Complex I causes the accumulation of αKG associated with the destabilization of 
HIF-1α that renders cancer cells unable to adapt to hypoxia, a condition we termed 
pseudonormoxia, and ultimately blocks tumor growth in vivo.  
This project thus aims to propose a metabolic-based approach to tackle cancer cell 
proliferation through a provoked accumulation of exogenous αKG under hypoxia condition. 
We speculated that high levels of αKG would result in a boosted PHDs activity with 
subsequent activation of HIF-1α protein degradation cascade. Although the ketoacid 
hydrophilic properties constitute a limitation to its membrane permeability, we generated 
ester analogues of αKG (αKGlogues), in which the metabolite is linked to such hydrophobic 
carriers via an ester bond allowing to optimise its physicochemical properties and thereby its 
delivery to the intracellular compartment due to the action of esterases. Consequently, a panel 
of 7 different αKG-monoesters were synthesised for the purpose of this study, each one 
bearing a structurally distinct carrier, and their ability to impede HIF-1α stabilisation in low 
oxygen tension along with cancer cell growth was assessed. Simultaneously, the αKGlogues 
safety was tested on non-cancer cells counterpart. Further, the respective abundances of TCA 
cycle intermediates and the molecular consequences likely engendered by such a metabolic 
state in cancer cells were also investigated. Finally, taking this study a step further in the 
perspective of proposing an αKG-based adjuvant anti-neoplastic therapy we aimed at 
translating our main hypothesis in more complex in vitro and in vivo cancer models that 
mimic the main features of solid tumors. In this regard, the potency of the most promising 
analogues and their cytotoxicity was established in 3D-derived tumor spheroids and in vivo 
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Chemical synthesis and stability analyses on αKGlogues 
Aiming to increase the permeability of exogenous αKG through the plasma membrane and 
thus achieve cytoplasmic accumulation of the metabolite, αKG was conjugated to chemical 
carriers of different hydrophobic indexes thereby generating monoester analogues 
(αKGlogues). The panel of 7 αKGlogues were synthetized as following: the appropriate halo-
derivative was added (1.1 eq) to a solution of α-ketoglutaric acid (10 mmol) and 
dicyclohexylamine (1.2 eq) in dimethyl formamide (50 mL), and the solution was heated at 
50°C for 5-16h. The mixture was concentrated under reduced pressure, the residue was 
resuspended in dichloromethane (100 ml) then washed with 0.5 N aqueous hydrochloric acid 
(50 mL). The organic layer was dried (sodium sulfate), and the solvent was removed under 
reduced pressure. The crude products were purified by flash column chromatography 
(petroleum ether/acetone, in various proportions), or by crystallization from acetone, ethanol, 
ethyl acetate or petroleum ether. The structures of the final compounds were confirmed by 
means of 1H-NMR spectra. The 1H-NMR spectra were recorded on a Varian MR 400 MHz 
(ATB PFG probe) (Data not shown). Following chemical synthesis (Figure 6) and purity 
assessment using NMR technology, compounds were dissolved in 100% ethanol or in a 1:1 
mixture of ethanol:DMSO (αKG-PP) then stored at -20°C. In their organic solvent the panel 
of αKGlogues displayed overall good stability levels, and only traces of degradation products 
were detected by thin layer chromatography (TLC) (Figure 7A) and quantitative mass 
spectrometric analysis revealed the esterified form of the compounds was prevalent to more 
than 99% (Figure 7B). Likewise, αKGlogues were stable up to 80% in tissue culture media 
reflecting minor basal hydrolysis and further confirming the compounds stability in aqueous 






Figure 6: Schematic representation of αKGlogues chemical synthesis. Free αKG was 
coupled to structurally distinct hydrophobic carriers thereby giving rise to monoester 
analogues of αKG: αKG-L (A), αKG-G (B), αKG-N (C), αKG-Cl (D), αKG-tB (E), αKG-P 









Figure 7: αKGlogues stability in organic solvent and in aqueous solution. (A) Thin 
layer chromatography showing mere traces of degradation of αKGlogues in organic 
solvent (marked with asterisks*). (B) αKGlogues quantitative stability data as assessed by 
mass spectrometric analysis respectively in organic solvent and in cell growth media 




The cellular models used in this study, namely primary human follicular thyroid cells (N-Thy 
3.1) and thyroid papillary carcinoma cells (TPC-1) were cultured in RPMI 1640 (Gibco, 
#21875091) while normal proximal tubule cells (HK-2) and human kidney carcinoma cells 
(UOK-257) of an individual with Birt-Hogg-Dubé syndrome (BHD) (Yang et al., 2008) were 
cultured in Dulbecco’s modified Eagle medium (DMEM) high glucose media (Gibco, 
#21969035). Growth medias were supplemented with 10% heat-inactivated Fetal Bovine 
serum (FBS) (Gibco, #16000044), 100 units/mL Penicillin/100µg/mL Streptomycin (Gibco, 
#15140122) and 2mM L-glutamine (Gibco, #25030024). Cells were tested on a regular 
basis through PCR for mycoplasma detection. Where indicated, cells were exposed to 2mM 
of commercial αKG-DM (Sigma-Aldrich, #349631). Deferoxamine (DFO) (Novartis, 
#A020417022) was used at 150µM for 24h as a positive control for PHDs inhibition. 
 
HIF-TM transduction 
A non-degradable version of HIF-1α was produced as previously described (Kurelac et al., 
2019) by site directed mutagenesis of residues P402A, P564G, and N803A, HIF-targeted 
sites for hydroxylation by prolyl hydroxylases (PHDs) and Factor inhibiting HIF (FIH1), 
respectively using Quickchange Site-Directed Mutagenesis kit (Agilent, #200518). Triple-
mutant HIF1A (TM-HIF) sequence was priorly transferred onto pMSCV-puro-Retroviral 
vector (Clontech, #PT3303-5), after which the empty vector and the vector containing HIF-
TM were used to transduce TPC-1 and UOK-257 cells by following phxA transduction 
protocol (Takara, #631317). Cells carrying the vectors were selected with 750 ng/mL 
puromycin (Sigma-Aldrich, #P8833) and maintained in medium supplemented with 250 
ng/mL puromycin. Clonal selection was performed to identify the clones with the highest 
HIF-TM protein levels in normoxia (21% O2) and pools of at least 3 clones were made for 
each cell line. 
 
SDS-PAGE & western-blotting 
Where indicated and post-hypoxia exposure in presence of either 200µM unconjugated αKG, 
αKGlogues or PP carrier, cells were harvested and lysed in RIPA buffer (Tris-HCl 50mM pH 
7.4, 1% Triton X-100, 0.1% SDS, 1mM EDTA pH 7, 150mM NaCl) supplemented with a 1X 
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phosphatases inhibitors (Alfa Aesar, #J63907) and 1X proteases inhibitors (Roche, 
#4693116001). Proteins were quantified with the Bradford method using BSA as a standard, 
denatured for 5 minutes at 95°C in Laemmli buffer, then loaded (30-40 µg) onto 
polyacrylamide gels (SDS-PAGE) and separated in a Mini-PROTEAN® Electrophoresis cell 
(Bio-Rad). Samples were subsequently transferred in full-wet system (Mini Trans-Blot® 
Cell, Bio-Rad) onto nitrocellulose membranes (Bio-Rad, #1620115), or Polyvinylidene 
floride (PVDF) (Bio-Rad, #1620177) for HIF-1α immunoblotting. Following 1h of blocking 
in 5% non-fat dry milk, 1X TBS (Tris Buffered Saline)-0.05% Tween® 20 (Sigma-Aldrich, 
#P1379), membranes were incubated overnight at +4°C with primary antibodies: anti-β-Actin 
(Sigma-Aldrich, #SAB5500001) 1:5000, anti-HIF-1α (GeneTex, #GTX127309) 1:2000; 
phospho-mTOR (S2448) (Cell Signaling Technology, #5536S) 1:1000; Phospho-Raptor 
(Ser792) (Cell Signaling Technology, #2083S) 1:1000; Phospho-p70S6K (S371) (Cell 
Signaling Technology, #9208S) 1:1000; Phospho-4E-BP1 (Thr37/46) (Cell Signaling 
Technology, 2855T) 1:1000. Anti-GAPDH (Sigma-Aldrich, #G8795) 1:10,000; anti-LC-3 
(Sigma-Aldrich, #L7543) 1:1000; Total mTOR (Cell Signaling Technology #2983S) 1:1000; 
Total Raptor (Cell Signaling Technology, #2280S) 1:1000; Total p70S6K (Cell Signaling 
Technology, #2708S) 1:1000; were incubated for 2h at room temperature (RT). Horseradish-
peroxide-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, anti-
rabbit #111-035-144, anti-mouse #115-035-146) were incubated at RT and proteins 
developed using ClarityTM Western ECL Substrate (Bio-Rad, #1705061). Images were 
acquired with Gel Logic 1500 Imaging system (Kodak, Ronchester, NY, USA). 
Densitometric quantification of the analysed proteins was performed using ImageJ software 
(NIH Image).  
 
Cell viability 
Cells were counted and plated (1 x 103 cells/well for cancer cell models and 2 x 103 cells/well 
for non-cancer counterparts) in 96-wells TC-treated plates (Falcon® 96 well, #353072) and 
left to adhere overnight. Subsequently, fresh media containing treatment (2µM, 20µM and 
200µM αKGlogues or corresponding carriers) was added and cells incubated at 37°C in 
standard conditions (21% O2 and 5% CO2). Experiments carried out under low oxygen 
tension (1% O2, 5% CO2) were performed in a hypoxic workstation (Ruskinn INVIVO2 300). 
Cell viability was assessed after 0, 24, 48 and 72h of treatment using sulforhodamine B 
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(SRB) viability assay. Briefly, at the indicated time points, cells were fixed with 50% 
trichloroactic acid (TCA) (Sigma-Aldrich, #T6399), then colored with SRB (Sigma-Aldrich, 
#S1402) which reflects intracellular protein content (Vichai and Kirtikara 2006). SRB is an 
aminoxanthene dye bearing two sulfonic groups which bind to basic amino acids under mild 
acidic conditions and dissociate in basic conditions. Following a 30-minutes staining step and 
several washes in 1% acetic acid, SRB was solubilized in 10mM Tris-HCl pH 10.4 and 
absorbance measured at 560 nm using microplate reader VICTOR3TM (PerkinElmer, Turku, 
Finland). Cell viability data were expressed as percentage of cell growth with respect to time 
0.  
 
Colony forming assay (clonogenic assay) 
Cells were seeded at a density of 250cell/well in 6-well plates. 24h post-seeding, treatment 
(200µM αKGLogues, PP carrier or vehicle) was added and cells incubated at 37°C in low 
oxygen tension (1% O2, 5% CO2, Ruskinn INVIVO2 300 Hypoxia workstation) for 7 days. 
Cells were then fixed with 50% TCA and the number of colonies counted. To evaluate 
protein content, colonies were stained with SRB dye after which absorbance reflecting colony 
size, was measured as described above. 
 
Cell migration (wound-healing assay)  
40-50 x 103 cell/well were plated onto Incucyte® ImageLock 96-well plates (Sartorius, 
#4379) to reach sub-confluency. The subsequent day, a homogenous wound was realized in 
all wells using Incucyte® WoundMaker (Sortorius), initial media discarded, and cell 
monolayers washed once with Phosphate Buffer Saline (PBS) after which treatment was 
added. Cells were then incubated at 37°C with a fresh growth media supplemented with 1% 
FBS containing either vehicle or treatment (200µM αKG-tB, αKG-PP or PP carrier). Wound 
confluence was monitored every hour for 24h using the Incucyte® S3 Live cell Analysis 






LC-MS metabolomics analyses  
For the purpose of this experiment, 5 x 105 cells were plated in 6-well plates and kept at 37°C 
in controlled O2 and CO2 conditions. 24h later, initial media was replaced, and respective 
treatments added, namely 200µM αKG-PP alone or in combination with 3-methyl, 2-
oxovaleric acid (KMV, 2mM) (Sigma-Aldrich, #K7125), an αKG dehydrogenase complex 
(αKGDHC) inhibitor that was used as a positive control to induce endogenous accumulation 
of αKG. Consequently, 1- and 3-hours post-treatment in high oxygen tension (21% O2), cells 
were counted and accordingly metabolites extracted with an appropriate volume of ice-cold 
extraction solution composed of 50% methanol, 30% acetonitrile, 20% ultra-pure H2O and 
5µM d8-Valine as an internal standard. Briefly, following 3 washes in PBS, extraction 
solution was added (1mL/million cells) and cells incubated on dry ice for 15 minutes. Cells 
were then scraped, collected in tubes, kept under agitation for 15 minutes at +4°C then 
incubated at -20°C for 1h. Finally, samples were centrifuged for 10 minutes at 16,000 rpm at 
+4°C and supernatants collected to be analyzed. Liquid chromatography-mass spectrometry 
(LC-MS) analyses were performed using an QExactive Orbitrap mass spectrometer 
(Thermofisher Scientific) as previously described (Sciacovelli et al., 2016). To determine 
αKG intracellular concentration, standard curves were realized with commercial αKG-DM 
(Sigma-Aldrich, #349631) and data were normalized to mean cell volume. 
 
Nuclear morphology assessment  
30 x 103 cells were plated on glass slides (15x15mm) and left overnight, after which initial 
growth media was replaced with a fresh one containing vehicle, 200µM αKG-PP or PP 
carrier. 72h post-treatment in high oxygen tension (21% O2), cells were fixed for 15 minutes 
in 4% formaldehyde, subsequently washed 3 times in PBS then incubated with DAPI 
(1µg/mL) for 10 minutes. Following another 3 washes in PBS, slides were mounted using a 
50% glycerol solution. Nuclei morphology upon treatment was then analyzed and images 







Flow cytometric analysis of apoptotic cell death   
24h-post seeding, cells were incubated with treatment (vehicle, 200µM αKG-PP or PP 
carrier) and kept in culture under high oxygen tension (21% O2, 5% CO2). 72h after treatment 
initiation, cells were harvested, counted, washed twice in PBS and centrifuged 5 minutes at 
300 xg. Cell pellets were then resuspended in provided binding buffer and the prepared cell 
suspensions co-stained with Annexin V (AV)/Propidium iodide (PI) for 20 minutes following 
manufacturer’s instructions (Annexin V Apoptosis Kit [FITC]) (Novus, #NBP2-29373) after 
which flowcytometric analysis was performed using an S3 cell sorter (Bio-Rad).  
 
β-galactosidase-associated senescence assay  
8 x 103 cells were plated onto 24-well plates and treatment (200µM of αKG-PP or PP carrier) 
added the subsequent day, after which cells were incubated at 37°C in controlled O2 and CO2 
conditions (21% and 5%, respectively). At experiment endpoint (72h), treatment-containing 
media was removed, and cells washed once in PBS then fixed for 15 minutes with the 
provided fixative solution (Senescence Detection Kit, Abnova, #KA0899). After two washes 
in PBS, cells were stained overnight at 37°C with a staining solution according to 
manufacturer’s instructions for the detection of senescence-associated β-galactosidase 
activity. Images were captured using a light microscope. 
 
Multicellular cancer-derived spheroids  
To generate cancer-derived spheroids, kidney and thyroid cancer cells were seeded in 96-well 
Ultra Low Attachment plates (Corning, # CLS3474) in a mix of appropriate tissue culture 
media and 2.5% (v/v) basement membrane extract (Geltrex™) (Thermofisher, #A1413202) to 
mimic extracellular matrix. Cells were then centrifuged at 130 xg for 10 minutes at RT and 
incubated at 37°C for 72h to allow cell aggregation and formation of homogenously sized 
single spheroids (Figure 8) after which αKGlogues treatment was initiated. Cytotoxicity 
induced by αKGlogues and positive control (200nM staurosporine) was evaluated using 
Promega’s CytoTox-Glo™ bioluminescence assay (Promega, #G9291) according to 
manufacturer’s instructions. In addition, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay was used as a complementary method to determine residual live cells 
in 3D models. Upon treatment with αKG-PP, kidney-derived cancer spheroids were harvested 
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and stained with MTT dye for 4 hours at 37°C. Exceeding dye was subsequently eliminated 
and reduced MTT accumulated inside the cells was dissolved in DMSO. Finally, MTT 
absorbance reflecting metabolically active cells was measured at 560 nm using microplate 
reader VICTOR3TM (PerkinElmer, Turku, Finland). Spheroids size was determined using 
ImageJ free software (NIH). 
 
 
Figure 8: Generation of multicellular single spheroids as in vitro 3D cancer models. 
Cancer cells seeding in a mixture of growth media and basement membrane extract 
(Matrigel®) allows the formation of homogenously sized single spheroids in 96-well plates in 
order to test αKGlogues antiproliferative capacity. Servier Medical Art templates 
(https://smart.servier.com/) were used to generate this figure.  
 
Drosophila imaginal wing discs as tumor model 
Drosophila imaginal wing discs are the larval primordium of adult fly wing. They are 
composed of pseudo-stratified columnar epithelium morphologically and biochemically 
comparable to mammalian epithelia (Wodarz and Näthke 2007) and represent a good model 
for proliferation studies. During larval development, the imaginal wing discs are subdivided 
by the anterior-posterior border (A/P) into a posterior (P) and anterior (A) compartment while 
the dorsal-ventral border divides the disc into a dorsal and a ventral compartment. The dorsal 
and ventral compartments are determined by Apterous (Ap) expression in the dorsal 
compartment of the organs (Butler et al., 2003).   
To induce tumor growth in wing discs, UAS-Gal4 genetic system was used (Brand and 
Perrimon, 1993). The two components of this system are the yeast transcriptional factor Gal4 
and its specific Upstream Activating Sequences (UAS). The driver line contains the Gal4 
sequence under the control of a specific promoter which permits its expression in specific 
tissues. The responder line, instead, contains the UAS sequence upstream of a specific 
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transgene. The two lines are crossed, and transcription is activated in the progeny. In the used 
model, the contemporary lethal giant larvae knockdown (lglKD), an evolutionary preserved 
polarity gene, and RasV12 mutation under the control of apterous (ap) promoter were induced 
to mimic an oncogenic cooperation mechanism. lglKD and RasV12 expression in the dorsal 
compartment of the wing discs (in green in Figure 9) allows an unrestrained larval organ 
overgrowth and a complete altered loss of tissue architecture (Figure 9B) with respect to the 
wild-type counterpart (Figure 9A). The larval development of ap-lglKD, RasV12 individuals 
lasts 8-9 days unlike wild-type larvae which take 5 days to complete the larval stages at 25°C. 
ap-lglKD, RasV12 larvae die at pre-pupa stadium showing wing discs with tumor dorsal 
compartment filling the entire organs (Figure 9B). To boost the tumor phenotype the 
experiments was performed at 29°C.  
 
 
Figure 9: Drosophila epithelial tumor model. Wild-type (A; ap-GFP) and tumor (B; ap-
GFP, lglKD, RasV12) imaginal wing discs.  The dorsal compartments are marked in green 
(GFP+). The wing disc structures are highlighted by a dotted line. Magnification is 400X. 
 
Fly manipulation and volume analysis 
6 days after egg laying (AEL), tumor larvae were selected and divided into two groups of 25 
individuals each: a control and a treated group which received vehicle and 200µM αKG-PP, 
respectively. 2 days after the treatment, the wing discs were isolated, photographed, and 
minor and major axes were measured using ImageJ free software (NIH). For volume 






GraphPad Prism 8.0 was used to perform statistical analyses and graphs generation. One-way 
ANOVA was performed for multiple comparison of HIF-1α/β-Actin densitometric 
quantification as well as of clonogenic assay data. Two-way ANOVA was performed to 
analyze cell viability experiments and compounds efficacy. Finally, an unpaired t-test was 
performed to compare two groups unless stated otherwise. Statistical significance was 




































Selected αKGlogues are able to prevent HIF-1α stabilization in hypoxia 
We previously demonstrated that increased levels of intracellular αKG in respiratory complex 
I defective models are associated with reduced HIF-1α stabilization in hypoxia (Kurelac et 
al., 2019). Thus, we hypothesize that such condition, termed pseudonormoxia, can be 
obtained through the supplementation of αKG to cells. However, because of its low 
hydrophobicity, αKG is poorly permeable through the plasma membrane and we pursued the 
strategy of conjugating the metabolite with hydrophobic substituents to improve its 
permeability. To investigate the ability of cell permeable αKGlogues to induce a 
pseudonormoxic state, HIF-1α protein levels in hypoxia (1% O2) were analysed in thyroid 
papillary carcinoma (TPC-1) and kidney carcinoma (UOK-257) cells upon incubation with 7 
different αKGlogues. Commercial αKG-DM was used as a reference for compound’s 
effectiveness. HIF-1α levels assessed by immunoblotting, revealed that at the dose of 200µM, 
αKGlogues displayed different effects on HIF-1α protein stabilisation in hypoxia (Figure 10) 
after 60 and 90 minutes of treatment. In TPC-1 cells, analogues αKG-G, αKG-N, αKG-L, 
αKG-tB and αKG-Cl significantly reduced HIF-1α destabilisation after 60 and 90 minutes of 
incubation in hypoxia with respect to the untreated cells (Figure 10A-C). However, among 
these compounds only αKG-N and αKG-Cl were more effective than commercially available 
αKG-DM (Figure 10A-C).  By contrast, αKG-P and αKG-PP showed a paradoxical effect, by 
increasing HIF-1α protein levels after 90 minutes of treatment (Figure 10A-C). In UOK-257 
cells, αKG-PP stood out as the most potent compound, being able to significantly reduce HIF 
expression after 60 minutes with respect to control and maintain this effect up to 90 minutes 
(Figure 10D-F). Interestingly, while the impact of 200µM of αKG-G and αKG-Cl was noted 
only after 90 minutes of treatment in hypoxia, the effect of αKG-N and αKG-P was transient, 
since they were effective after 60 minutes in destabilizing HIF-1α, but the levels of the 
protein increased again after 90 minutes of incubation (Figure 10D-F). However, αKG-PP, 
αKG-G and αKG-Cl were all more effective than αKG-DM, which in turn seemed to not 
significantly affect on HIF-1α levels (Figure 10D-F). We tested the effect of such compounds 
also in non-cancer models derived from the same tissue, namely N-Thy 3.1 for thyroid and 
HK-2 for kidney. Overall, αKGlogues did not impair HIF stabilisation in the healthy thyroid 
cells up to 90 min of exposure in hypoxia, with the exception of αKG-L and αKG-Cl which 
showed a transient slight reduction of HIF-1α abundance at 60 minutes (Figure 11A-C). 
Similarly, in the healthy kidney counterpart, most compounds had no effect on HIF-1α 
destabilisation for the duration of treatment, with the only remarkable exception of 60 
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minutes of exposure to αKG-PP that induced a transient reduction in HIF-1α levels (Figure 
11D-F).  
Hence, from the first phase of screening, the most potent compounds limiting HIF-1α 
accumulation in hypoxia were selected for further investigation, namely αKG-N, αKG-L, 
αKG-Cl and αKG-tB on thyroid cancer cells and αKG-G, αKG-N, αKG-Cl, αKG-P and αKG-







Figure 10: HIF-1α expression in cancer cell models treated with αKGlogues panel under 
low oxygen tension reveals promising compounds. Western blot and related densitometric 
analysis of HIF-1α levels in TPC-1 (A-C) and UOK-257 (D-F) cells at 60- and 90-minutes 
post-treatment with 200µM αKGlogues in hypoxia (1% O2). β-Actin was used as a loading 
control. Data (mean ± SD) are expressed as HIF-1α/β-Actin ratio calculated at treatment time 
(T) and normalised on their respective untreated counterpart at T0 (30 minutes of hypoxia 








Figure 11: HIF-1α levels in non-cancer epithelial cells are not influenced by treatment 
with αKGlogues. Western blot and related densitometric analysis of HIF-1α levels in N-Thy 
3.1 (A-C) and HK-2 (D-F) cells at 60- and 90-minutes post-treatment with 200µM 
αKGlogues in hypoxia (1% O2). β-Actin was used as a loading control. Data (mean ± SD) are 
expressed as HIF-1 α/β-Actin ratio calculated at treatment time (T) and normalised on their 
respective untreated counterpart at T0 (30 minutes of hypoxia baseline) (n=2). 
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αKGlogues specifically alter cancer cells growth and in vitro tumorigenic properties 
After establishing αKGlogues block HIF-1α stabilisation in hypoxia at a dose of 200µM in 
our cancer cell models, the most effective compounds selected were then tested for their 
ability to alter cancer cell growth in vitro. Hence, in the presence of increasing concentrations 
of compounds, the growth of thyroid and renal cancer cells was determined along with their 
non-cancer counterparts, namely TPC-1/N-Thy 3.1 and UOK-257/HK-2, respectively. Cell 
viability following treatment was evaluated after 24, 48 and 72h of incubation using the SRB 
assay both in hypoxia (1% O2) and normoxia (21% O2). Despite the significant reduction of 
HIF-1α levels in hypoxic conditions, αKG-N did not affect the growth of TPC-1 cells after 
72h neither in hypoxia nor in normoxia even at the highest dose (200µM) (Figure 12A-B). 
Likewise, αKG-L was ineffective at lower doses both in hypoxia and normoxia, even if at 
200µM the analogue slightly delayed the growth of TPC-1 cells after 3 days in hypoxia 
(Figure 12C-D). These two compounds resulted ineffective in the non-cancer counterpart N-
Thy 3.1 (Figure 13A-D). Conversely, αKG-Cl induced a dose- and time-dependent restriction 
of TPC-1 cell growth (Figure 12E-F). In particular, 200µM of αKG-Cl was able to 
completely block the growth of TPC-1 cells already after 24h of treatment both under 
hypoxic (1% O2) and normoxic conditions (21% O2), while at lower doses this compound 
resulted more effective in hypoxia. Similarly, 20µM αKG-Cl displayed an early severe effect 
after 24 and 48 hours of incubation of N-Thy 3.1 cells, while high doses of the compound 
drastically altered their proliferation (Figure 13E-F). Low doses (2 and 20µM) of αKG-tB 
provoked a mild reduction of TPC-1 cell growth after 72h in low and high oxygen tension, 
while high doses (200µM) displayed a strong alteration on cells growth already after 24h of 
treatment independently of oxygen level (Figure 12G-H). Conversely, N-Thy 3.1 cells were 
not affected by low doses of αKG-tB, and only 200µM of the analogue correlated with a mild 
growth reduction independently of oxygen conditions as cells maintained their proliferation 
(Figure 13G-H). To discriminate the effect of the compounds on cancer vs non-cancer cells, 
compounds efficacy at 72h representing the percentage of dead cells induced by 200µM of 
treatment was calculated with respect to the untreated control in both cancer and non-cancer 
cells (Figure 14A-B). This analysis identified αKG-tB as the only compound able to 
selectively target TPC-1 cells without being deleterious for N-Thy 3.1 cells, as highlighted by 







Figure 12: High doses of αKG-Cl and αKG-tB significantly alter the growth of papillary 
thyroid carcinoma cells despite of oxygen level. TPC-1 cell viability was determined by 
using SRB assay up to 72h of treatment with different doses of αKG-N (A, B), αKG-L (C, 
D), αKG-Cl (E, F), αKG-tB (G, H) respectively in hypoxia (1% O2) and normoxia (21% O2). 
Data (mean ± SE) are expressed as a percentage of cell growth with respect to time 0 
considered as 100% (n≥3). p-value was calculated with a two-way ANOVA. *p≤0.05, 





Figure 13: Proliferation of non-cancer thyroid cells is severely impaired by high doses of 
αKG-Cl. N-Thy 3.1 growth rate was determined by using SRB assay up to 72h of treatment 
with increasing doses of αKG-N (A, B), αKG-L (C, D), αKG-Cl (E, F), αKG-tB (G, H) 
respectively in hypoxia (1% O2) and normoxia (21% O2). Data (mean ± SE) are expressed as 
a percentage of viable cells with respect to time 0 considered as 100% (n≥3). p-value was 





Figure 14: αKGtB selectively alters the proliferation of papillary thyroid carcinoma 
cells. (A-B) Efficacy of selected αKGlogues was determined in thyroid cancer (TPC-1) and 
non-cancer (N-Thy 3.1) cells under low (1% O2) (A) and high oxygen tension (21% O2) (B), 
respectively. Data (mean ± SEM) represent the percentage of dead cells induced by 200µM 
αKGlogues at 72h calculated with respect to the untreated control for each cell line (n≥3). A 
two-way ANOVA was used to calculate p-value. *p≤0.05, **p≤0.01, ***p≤0.001 
 
With regards to the growth curves of the UOK-257 cells, the kidney carcinoma cells were 
insensitive to increasing doses of αKG-N, αKG-G and αKG-P up to 200µM either in hypoxia 
(1% O2) or normoxia (21% O2) (Figure 15A-D, G-H) and the three compounds resulted 
equally non-effective on the proliferation of the epithelial kidney counterparts (Figure 16A-
D, G-H). By contrast, αKG-Cl induced a mild yet significant alteration in the growth of 
UOK-257 cells at low doses (2 and 20µM) 48 and 72h after treatment initiation in hypoxia, 
while a dose of 200µM caused a severe block in the proliferation of the kidney carcinoma 
cells during the first 2 days of the treatment in hypoxia to finally induce cell death, an effect 
that was observed already 24h post-treatment in normoxia (Figure 15E-F). Similarly to αKG-
Cl, 2 and 20µM of αKGlogue-PP significantly delayed the proliferation of the UOK-257 cells 
at day 3 of treatment both in high and low oxygen tension whilst 200µM of compound 
blocked the growth of the cancer cells and ultimately resulted in a lethal effect at 72h (Figure 
15I-J). With regards to the effect of αKG-Cl and αKG-PP on the non-cancer kidney 
counterpart, HK-2 cells displayed a slightly slowed growth rate after 72h of exposure to low 
doses of the analogues in hypoxia, and although cells suffered a drop in proliferation with 
200µM of αKG-Cl in hypoxic as well as in normoxic conditions (Figure 16E-F), the effect 
remained relatively harmless as reflected by compound’s efficacy (Figure 17A-B). Most 
importantly, αKG-PP affected the non-cancer renal cells viability to a lesser extent. In fact, it 
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shows to be more specific on the UOK-257 cells (80%) than on the non-cancer control (50%) 
in low oxygen levels (Figure 17A-B). Overall, 200µM of αKG-Cl and αKG-PP specifically 
impaired the growth of the kidney carcinoma cells while displaying safety on the epithelial 








Figure 15: High doses of αKG-Cl and αKG-PP block the growth of kidney carcinoma 
cells indifferently from oxygen tension. UOK-257 cell viability was determined using SRB 
assay up to 72h of treatment with growing concentrations of αKGlogues: αKG-G (A, B), 
αKG-N (C, D), αKG-Cl (E, F), αKG-P (G, H) and αKG-PP (I, J) respectively in hypoxia 
(1% O2) and normoxia (21% O2). Data (mean ± SE) are expressed as a percentage of viable 
cells with respect to time 0 considered as 100% (n≥3). p-value was calculated using a two-




Figure 16: High doses of αKG-Cl and αKG-PP mildly delay the growth of epithelial 
kidney cells. HK-2 growth rate was determined using SRB assay up to 72h of treatment with 
increasing doses of αKGlogues: αKG-G (A, B), αKG-N (C, D), αKG-Cl (E, F), αKG-P (G, 
H) and αKG-PP (I, J) respectively in hypoxia (1% O2) and normoxia (21% O2). Data (mean 
± SE) are expressed as a percentage of viable cells with respect to time 0 considered as 100% 





Figure 17: αKG-Cl and αKG-PP selectively impair the proliferation of kidney 
carcinoma cells in hypoxia. (A-B) Efficacy of selected αKGlogues was determined in 
kidney cancer (UOK-257) and non-cancer (HK-2) cells under low (1% O2) (A) and high 
oxygen tension (21% O2) (B), respectively. Data (mean ± SEM) represent the percentage of 
dead cells induced by 200µM αKGlogues at 72h calculated with respect to the untreated 




To correlate the effect of αKGlogues on cell viability with HIF-1α stabilization, we evaluated 
the levels of HIF-1α in hypoxia upon treatment with the most effective compounds for long 
incubation times (6h and 12h). αKG-Cl and αKG-tB were chosen for TPC-1 cells, while 
αKG-Cl and αKG-PP were selected for UOK-257 cells. In TPC-1 cells, HIF-1α expression 
was mildly reduced in presence of αKG-Cl at 6h but recovered after 12 hours (Figure 18A, 
18C), while αKG-tB sustained HIF-1α degradation up to 12h as the protein levels were two-
fold lower with respect to untreated cells (Figure 18B-C). Similarly, in UOK-257 cells αKG-
Cl significantly reduced the protein abundance after 12h of treatment while αKG-PP was as 
potent at 6 and 12h of exposure reducing HIF-1α levels to their half with respect to the 
untreated (Figure 18E-F). Interestingly, at these time points unconjugated αKG was unable to 
affect the hypoxic HIF-1α protein stabilisation in both TPC-1 and UOK-257 cells, confirming 






Figure 18: Selected αKGlogues sustain HIF-1α destabilization in low oxygen tension. 
Western blot analysis of HIF-1α expression in TPC-1 cells exposed to 200µM αKG-Cl (A), 
αKG-tB and unesterified αKG (B). Western blot analysis of HIF-1α expression in UOK-257 
cells treated with 200µM αKG-Cl (D), αKG-PP or unconjugated αKG (E) for 6 and 12 hours. 
Densitometric quantification of HIF-1α protein levels both in TPC-1 (C) and UOK-257 (F) 
cells was performed using ImageJ software and normalised to loading control β-actin. Results 
(mean ± SEM) are representative of at least 2 experiments. A two-way ANOVA was 




To test the ability of our selected hits to alter malignant cells tumorigenic properties in vitro, 
TPC-1 and UOK-257 cells were incubated in low oxygen conditions (1% O2) with 200µM of 
selected αKGlogues. To this aim, we performed a colony formation assay in hypoxia to 
assess clonogenic properties and a wound-healing assay to determine cell migration upon 
treatment with selected compounds. In colony formation assay, cells were incubated for 7 
days with αKGlogues and colonies were stained with SRB in order to determine the colony 
number and the quantification of protein content as an indicator of colony size. In these 
experiments, αKG-Cl was not investigated since we identify an intrinsic detrimental effect on 
the healthy thyroid cells even at low doses, thereby only leaving αKG-tB and αKG-PP as the 
most promising compounds on the TPC-1 and UOK-257, respectively. In line with the 
viability data, 200µM αKG-tB drastically reduced the number and the size of colonies of 
TPC-1 cells (Figure 19A). The same parameters were severely affected by the treatment of 
UOK-257 cells with 200µM αKG-PP (Figure 19B). These results suggest that the analogues 
able to induce HIF-1α degradation in hypoxia up to 12h and to block cell growth are also able 
to impinge the clonogenic ability of cancer cells. Then, we analysed cancer cell mobility in a 
wound-healing assay. Cells were seeded in order to reach confluence after 24h, when wound 
was produced followed by incubation with 200µM of selected compounds. The analysis of 
wound confluence after 24h from the wounding event revealed that TPC-1 cells treated with 
200µM αKG-tB showed a wound confluence of about 40% while untreated cells were almost 
able to close the wound with a confluence of 70% (Figure 19C).  Similarly, after 24h the 
wound surface in untreated UOK-257 was at 45% confluence, while UOK-257 treated with 
200µM αKG-PP showed a wound with a confluence of 15% (Figure 19D) highlighting the 










Figure 19: αKGlogues severely hamper tumorigenic properties of thyroid and kidney 
cancer cells in vitro. (A, B) Clonogenic assay was performed on untreated (UT) and treated 
TPC-1 and UOK-257 cells after incubation with 200µM αKG-tB or αKG-PP respectively, for 
7 days in low oxygen conditions (1% O2). Colony number was counted, and colony size 
determined by SRB dye absorbance measured at 560 nm. An unpaired t-test was performed 
for statistical analysis of data (mean ± SEM) (n=3) *p≤0.05, **p≤0.01, ***p≤0.001, 
****p≤0.0001. (C, D) Cell migration was evaluated through a wound-healing assay in 
presence of the most promising analogues: αKG-tB in TPC1 and αKG-PP in UOK-257 under 
high oxygen tension (21% O2). Wound making was realised on cell monolayers at time 0 (T0) 
and wound closure monitored for 24h using Incucyte® S3 Live cell Analysis System. Wound 
confluence in TPC-1 (C) and UOK-257 (D) monolayers was calculated at experiment 
endpoint using Incucyte® S3 Live cell Analysis System Software. An unpaired t-test was 




Long-term effect on cancer cell viability is partially related to HIF pathway alteration 
Selected αKGlogues, namely αKG-PP and αKG-tB, induced HIF-1α degradation in hypoxia, 
which correlated with impaired cell proliferation and repressed tumorigenic properties. In 
order to investigate whether such alterations are caused by the shut-off of HIF-1α signalling 
the two cell models were transduced to stably express a triple-mutant non-degradable version 
of HIF-1α (HIF-TM). After showing the cells successfully stabilise HIF-1α in high oxygen 
levels (Figure 20A, 20E), their proliferation rate was subsequently determined in presence of 
the selected compounds and the respective hydrophobic carriers (Figure 20B-C, 20F-G). 
Surprisingly, TPC-1 cells expressing HIF-TM were as sensitive to αKG-tB as to tB 
hydrophobic carrier (Figure 20B-D). Indeed, 200µM of both treatments blocked the growth 
of the transduced cell line, leaving only 10% viable cells after 72h and thus suggesting a non-
specific effect of the carrier. Moreover, parental TPC-1 cells displayed a similar growth 
alteration in response to treatment with 200µM αKG-tB or the corresponding hydrophobic 
carrier (Figure 20B-D). These data suggest that the anti-proliferative effect observed with 
αKG-tB is independent of HIF-1α destabilisation and solely due to the activity of the carrier, 
and thus not related to increased intracellular levels of αKG. By contrast, in the parental 
UOK-257 the residual viability in response to treatment with 200µM αKG-PP was of 10% 
viable cells, while the counterpart expressing HIF-TM is less affected by the compound with 
a 60% residual viable cells after 72h (Figure 20F, 20H). Interestingly, PP carrier alone 
similarly reduced to 60% the viability in both parental and HIF-TM expressing cells, thereby 
suggesting this molecule alters kidney cancer cell proliferation independently of HIF-1α 
status by 40% (Figure 20F-H). Hence, PP carrier appears to contribute in part to the reduced 
cell proliferation and displays an additive effect to that of αKG. In light of these results, 






Figure 20: Hydrophobic carriers contribute to the alteration of cancer cell growth 
independently of HIF-a signalling. Growth curves of TPC-1 (A) and UOK-257 (E) cells 
transduced with non-degradable HIF-1α (HIF-TM) in presence of 200µM αKG-tB and tB 
carrier (B, C) or αKG-PP and PP carrier (F-G) in normoxia (21% O2). Curves are plotted 
along with the corresponding parental cell lines expressing wild-type HIF-1α exposed to the 
same treatments in hypoxia (1% O2). A two-way ANOVA was used for statistical analysis of 
data (mean ± SEM) (n≥3) *p≤0.05, **p≤0.01, ***p≤0.001****p≤0.0001. Efficacy of 
treatment with 200µM αKG-tB and αKG-PP along with their respective carriers on TPC-1 
(D) and UOK-257 (H) cell lines. Data (mean ± SEM) represent the percentage of dead cells 
induced by treatment at 72h calculated with respect to the untreated control in transduced and 




The evaluation of colony formation and cell migration of UOK-257 cells treated with 200µM 
PP carrier confirmed its synergistic anti-proliferative activity. Indeed, UOK-257 cells treated 
with 200µM PP carrier showed an impairment in their clonogenic properties, which is 
however significantly lower compared with αKG-PP treatment (Figure 21A). Similarly, cell 
migration was impaired in cells treated with 200µM PP carrier, but not as much as those 
incubated with αKG-PP (wound confluence 30% and 15%, respectively) (Figure 21B), 
thereby suggesting an additive effect in this property as well. Lastly, the PP carrier alone 
resulted mostly well tolerated by epithelial non-cancer cells HK-2 and N-Thy 3.1 cells which 
were respectively viable to 70% and 50% after 72h of treatment with 200µM of carrier 



















Figure 21: PP carrier per se displays a synergistic effect on kidney carcinoma cell 
migration properties. (A) Clonogenic abilities were determined in presence of 200µM αKG-
PP or PP carrier for 7 days in low oxygen conditions (1% O2). Colony number was counted, 
and colony size determined by SRB dye absorbance measured at 560 nm. A one-way ANOVA 
was performed for statistical analysis of data (mean ± SEM) (n=3) *p≤0.05, **p≤0.01, 
***p≤0.001, ****p≤0.0001. (B) Cell migration in UOK-257 cells was evaluated through a 
wound-healing assay in presence of 200µM αKG-PP or PP carrier under high oxygen tension 
(21% O2). Wound making was realised on cell monolayers at time 0 (T0) and wound closure 
monitored for 24h using Incucyte® S3 Live cell Analysis System. Wound confluence in 
UOK-257 monolayers (B) was calculated at experiment endpoint using Incucyte® S3 Live 
cell Analysis System Software. A one-way ANOVA was used for statistical analysis of data 
(mean ± SEM) (n=3) *p≤0.05, **p≤0.01, ***p≤0.001. (C-D) Cell viability of normal 
epithelial cells HK-2 (C) and N-Thy 3.1 (D) in high oxygen tension (21% O2) was 
determined after 72h of treatment in presence of 200µM PP carrier using SRB assay. An 




 αKGlogue PP provokes αKG intracellular accumulation and imbalanced αKG/SA ratio 
We previously described that CI-deficient cells are unable to stabilise HIF-1α even in low 
oxygen tension as a result of PHDs chronic activation. At the metabolic level, these cells 
displayed increased αKG levels and reduced succinate reflecting a disrupted TCA cycle. To 
demonstrate that the selected αKG-PP permeates the cell membrane and causes increased 
αKG intracellular levels, LC-MS-based metabolomics analysis was carried out on UOK-257 
cells after exposure to the compound for 1h and 3h. In these experiments, we used 2mM 3-
methyl, 2-oxovaleric acid (KMV) to inhibit the αKG dehydrogenase complex (αKGDHC) 
and push the accumulation of endogenous as well as exogenous αKG, and we considered it as 
a positive control. UOK-257 cells incubated with 200µM αKG-PP for 1h or 3h showed a 
time-dependent increased levels of αKG (Figure 22A), reduced succinate levels (Figure 22B) 
correlating with an elevated αKG/succinate ratio (Figure 22C), while not altering 2-
hydroxyglutarate (2-HG) levels (Figure 22D). In such context, the latter result indicates that, 
once uptaken, αKG is quickly metabolised by αKGDHC. Indeed, 2-HG levels rapidly 
increase when cells are treated with the combination of 200µM αK-PP and 2mM KMV 
(Figure 22D). Interestingly, the observed peak in αKG levels after 3 hours of treatment 
corresponds to reduced HIF-1α abundance that is maintained even after 6 hours, while PP 
carrier has no effect at the same time points, thereby confirming that αKG-PP, and not the 
hydrophobic carrier, interferes with HIF-1α stabilisation likely by activating prolyl 
hydroxylases (Figure 22E-F). Metabolomic analysis revealed that after 1 hour of incubation 
with αKG-PP only a slight decrease of glutamate was detected, while 3 hours post-treatment 
a consistent alteration of the TCA cycle was observed. Indeed, aconitate and glutamate levels 
were significantly reduced (Figure 23A, 23E), while fumarate and malate levels were 
increased (Figure 23C-D). Citrate and aspartate levels remained unchanged (Figure 23B, 
23F). Interestingly, inhibition of αKGDHC by KMV pushes the TCA cycle to its extreme, 
inducing after just 1 hour a profound depletion of citrate, aconitate, glutamate and aspartate, 








Figure 22: αKG-PP treatment triggered an increase of intracellular αKG correlated 
with HIF-1α destabilisation in kidney carcinoma cells. (A) Intracellular αKG levels after 1 
and 3 hours of exposure to 200µM αKG-PP were quantified using LC-MS approach under 
normoxia (21% O2). To determine αKG intracellular levels, a calibration curve of the 
ketoacid was prepared and raw data normalised to mean cell volume. 3-methyl, 2-oxovaleric 
acid (KMV; 2mM) was used as a positive control for human αKGDH inhibition. (B) 
Succinate (SA) and 2-hydroxyglutarate (2-HG) (D) relative abundance values correspond to 
metabolites ion intensity normalised to internal standard Valine-d8. (C) αKG/SA ratio was 
calculated by the proportion of relative abundances of each metabolite. Metabolomics data 
(mean ± SD) are representative of 6 technical replicates. A one-way ANOVA was performed 
for statistical analysis *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. (E) Western blot 
analysis of HIF-1α levels in UOK-257 cells untreated and treated with 200µM αKG-PP or PP 
carrier under hypoxia (1% O2) for 1, 3 and 6 hours and respective densitometric 
quantification of protein levels reported to loading control β-actin (F). Data analysis (mean ± 




Figure 23: αKG-PP causes TCA cycle rewiring in kidney carcinoma cells. Relative 
abundance of aconitate (A), citrate (B), fumarate (C), malate (D), glutamate (E) and aspartate 
(F) were obtained after 3 hours of treatment under normoxia (21% O2). Values correspond to 
metabolites ion intensity normalised to internal standard Valine-d8. Data (mean ± SD), are 
representative of 6 technical replicates. A one-way ANOVA was performed for statistical 
analysis *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. 
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The molecular mechanisms underlying αKG-PP effect imply the block of mTORC1 
pathway 
As reported in previous sections, αKG-PP and its corresponding carrier are capable of 
impairing cancer cell growth at high doses (200µM), and αKG-PP was much more potent in 
doing so. In this regard, and with the aim to investigate the modalities underlying the effect of 
αKG-PP on UOK-257 cell viability, we started by exploring apoptosis induction resulting 
from αKG-based treatment as previously reported in literature (Tennant and Gottlieb 2010). 
In this regard, DAPI-stained nuclear structures of untreated UOK-257 cells or treated with 
either αKG-PP or PP carrier did not show any sensitive alterations or apoptotic features up to 
72h of treatment in normoxia (21% O2) (Figure 24A) nor in hypoxia (1% O2) (data not 
shown) thereby eliminating a hypothetical apoptotic cell death that would be due to αKG-PP 
or corresponding carrier. Furthermore, a flow cytometry analysis was performed on UOK-
257 cells 72h post-treatment with 200µM of αKG-PP or PP carrier in normoxia (21% O2), 
using Annexin V (AV) as a marker for apoptotic cell death along with propidium iodide (PI). 
Both experiment and analysis were carried out in high oxygen tension since flow cytometer 
does not allow a controlled oxygen supply in order to maintain cells under low oxygen 
conditions. At the experiment endpoint, results revealed a shift in cell populations. While the 
untreated condition counted around 89% of live cells, this percentage was of 86.3% in cells 
treated with PP carrier and to 82.9% in αKG-PP-treated cells (Figure 24B). In this latest 
condition, the proportion of dead cells was twice as much as in the untreated control (5.73%) 
with 12.5% dead cells, while 200µM PP provoked 8.70% cell death (Figure 24B). These data 
thus support cell viability experiments previously described, showing that αKG-PP induces 
cell death on the one hand and confirming the contribution of PP carrier. However, it is worth 
to note that the proportion of dead cells induced by the analogue in this last case was less 
marked than in SRB viability assay.  Moreover, the induction of senescence in these cells was 
also investigated. In this frame, treated and untreated kidney carcinoma cells stained negative 
to senescence-specific β-galactosidase assay (Figure 24C, upper panel) 72h after treatment 
with either 200µM of αKG-PP or PP carrier in normoxia, thus ruling out this pathway as a 
possible mechanistic consequence of αKG accumulation. Similarly, no differences in LC-3 
protein levels or processing were observed up to 6h of treatment with αKG-PP or PP carrier 
in hypoxia (Figure 24C, lower panel) excluding the induction of autophagy as a consequence 
of αKG accumulation at least not as an early event during treatment. 
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Being a precursor of glutamine, αKG is tightly involved in amino acids metabolism. On the 
other hand, mammalian Target of Rapamycin Complex 1 (mTORC1), constitutes the master 
regulator of protein synthesis in response to nutrients availability and proliferation needs of 
rapidly growing cancer cells (Saxton and Sabatini 2017). Interestingly, analysing proteins of 
this pathway through western blot in a context of αKG accumulation surprisingly revealed 
treatment with αKG-PP and not PP carrier correlated with an inhibition of mTORC1 pathway 
after 1, 3 and 6 hours in hypoxia. Indeed, Raptor, one of mTORC1 associated regulatory 
proteins necessary for the complex binding to its targets, was phosphorylated at Serine 792 
only in samples treated with αKG-PP (Figure 24D), highlighting the protein inactivation and 
thus the shut-off of mTORC1 signalling. Next to that, no notable differences in total or 
phosphorylated mTOR levels were observed (Figure 24D). Such results thus suggest 
increased intracellular αKG levels in UOK-257 cells correlate with a rapid inhibition of 
mTORC1 signalling. Furthermore, the phosphorylated forms of p70S6K and 4E-BP1, two 
downstream substrates of mTORC1 involved in the initiation of cap-dependent translation 
and protein synthesis, were notably reduced in UOK-257 cells exposed to αKG-PP for 48h 
with respect to the untreated (Figure 24E), indicating αKGlogue PP represses mTORC1 
signalling and protein synthesis at 48h in low oxygen tension while no such effect was 
notable at earlier times, namely 16 and 24h of treatment. Surprisingly, PP carrier also 
appeared to downmodulate mTORC1 pathway in UOK-257 cells after 48h, although less 
marked than the analogue itself, suggesting once more an additive effect of the carrier in this 
context (Figure 24E). Notably, total and phosphorylated mTOR levels remained unchanged 






Figure 24: Molecular mechanisms underlying αKG-PP effect in UOK-257 cells imply 
the block of protein synthesis via mTORC1 signalling. (A) Nuclei morphology was 
visualized by DAPI staining upon exposure to 200µM αKG-PP and PP carrier for 72h under 
normoxia (21% O2). (B) Apoptotic death was evaluated using PI and AV as markers in flow 
cytometry after 72h of αKG-PP and PP treatment under normoxia (21% O2). (C), 
Senescence-specific β-galactosidase staining of UOK-257 cells untreated or treated with 
200µM αKG-PP and PP for 72h under normoxia (21% O2) (upper panel). Western blot 
analysis of autophagy marker LC-3 up to 6h of treatment with αKG-PP and PP under hypoxia 
(1% O2) (lower panel). (D, E) Western blot analysis of mTOR pathway at different times of 





αKG-PP displays anti-proliferative properties in cancer-derived spheroids and in vivo 
At this stage, we aimed at translating the use of αKG-PP in more complex models such as 3D 
cultures and animal models. Hence, multicellular spheroids derived from TPC-1 and UOK-
257 cells were generated in ULA plates. The obtained 3D models of approximately 200µm 
diameter were described to recapitulate several properties (oxygen and nutrients gradient, 
heterogenous cell population) of solid tumors in vivo. Spheroids were consequently treated 
with 200µM αKG-PP, while 200nM staurosporine (STS) was used as a positive control. In 
this regard, results revealed that the two tested models treated with αKG-PP showed no 
difference in the proportion of dead cells compared to the untreated control (Figure 25A-B) 
after 3 days of treatment, while 200nM STS induced a significant cell death. It is possible that 
at this dose, a treatment duration of 3 days is too short to see any effect on the growth of 
complex structures such as spheroids. Consequently, treatment was extended to longer 
periods, as most reports in literature often refer to 7 days as a mean duration. A subsequent 
experiment in which UOK-257-derived spheroids were maintained in presence of αKG-PP 
for 7 days confirmed the absence of significant differences in spheroids size 3 days post-
treatment (Figure 25C), whereas at day 7 the 3D cancer model exposed to αKG-PP and PP 
carrier looked significantly smaller in size compared to the untreated control (Figure 25C). 
These data are comforted by an MTT viability assay that showed the proportion of 
metabolically active cells was significantly lower in spheroids exposed to 200µM αKG-PP 
compared to untreated control. Moreover, the percentage of viable cells in presence of αKG-
PP was 50% less than in spheroids exposed to PP carrier after 7 days of treatment (Figure 
25C). Hence, these preliminary data strongly corroborate an anti-proliferative effect of αKG-
PP in the 3D kidney cancer model as well as a synergistic action of the PP carrier in this 







Figure 25: αKG-PP alters 3D spheroids size and viability. Size and cytotoxicity 
assessment in UOK-257 (A) and TPC-1-derived spheroids (B) after 3 days of treatment with 
200µM αKG-PP. 200nM staurosporine (STS) was used as a positive control. Quantitative 
analysis of dead cells was determined using Promega’s CytoTox-Glo™ bioluminescence 
assay. A one-way ANOVA was used for statistical analysis of data (mean ± SEM, n≥4) 
*p≤0.05, **p≤0.01, ***p≤0.001. Spheroids size (mean ± SD) was measured using ImageJ 
free software (NIH) and normalised to their size at Time 0. (C) Growth of UOK-257-derived 
spheroids up to 7 days of treatment (n=1) with 200µM αKG-PP and PP carrier. Percentage of 
viable cells at day 7 in UOK-257-derived spheroids was determined using MTT assay. Data 




 Drosophila melanogaster is considered a handful in vivo model to study the complex 
features of cancer thanks to signaling pathways and regulatory system preservation from 
human to flies (Mirzoyan et al., 2019). The use of specific and advanced genetic tools and its 
short life cycle (10 days at 25°C) make flies easy to manipulate. Drosophila is also an 
excellent model for drug screening studies because, in addition to closely reproducing the 
typical human cancer traits, it allows the analysis of a large number of individuals.  To 
investigate the consequence of αKG-PP treatment in vivo, tumor growth in the dorsal 
compartment of imaginal wing discs was induced. 6 days after egg laying (AEL) tumor 
individuals were selected and exposed to 200µM αKG-PP for 2 days. Wing disc isolation 
revealed a 34% decrease in tumor size of treated individuals with respect to the untreated 
counterpart as highlighted by volume analysis (Figure 26).  These preliminary data thus 
confirm αKG-PP potency to slowdown tumor growth in vivo. However, whether the 
analogue-mediated effect in Drosophila wing discs is due to increased cell death or to 
reduced proliferation remains to be determined. 
 
 
Figure 26: αKG-PP displays antiproliferative properties in vivo. Tumors isolated from ap-
lglKD, RasV12 untreated samples (A) or treated with 200µM αKG-PP (B) for 2 days. (C) 
Volume analysis of ap-lglKD, RasV12 tumor samples untreated (n=46) and treated with αKG-PP 




































Targeting hypoxic adaptation in cancer has long constituted an attractive approach to tackle 
tumor progression. Although focused approaches as represented by HIF inhibitors seem to 
constitute an interesting alternative, their use as single therapies in cancer patients is seriously 
limited by the high resistance rates and relapse. For this reason, now more than ever, the 
perspective of combining classical chemotherapy/radiotherapy to emerging complementary 
approaches among which targeting metabolism and hypoxia adaptation appears to be more 
convenient to enhance the chances of treatment success and are consequently being 
investigated in clinical trials.  
Here, we propose an adjuvant and safe metabolic-based therapeutic approach taking into 
account that TCA metabolites may also act as tumor growth modulators. In this framework, 
we have previously demonstrated that a severe mitochondrial CI impairment triggers an 
increase of both NADH/NAD+ and αKG/SA ratio, causing chronic HIF-1α degradation 
(pseudonormoxia) and in turn, tumor growth arrest (Porcelli et al., 2010) (Gasparre et al., 
2011) (Calabrese et al., 2013) (Iommarini et al., 2014) (Kurelac et al., 2019). To recapitulate 
this low-proliferative phenotype we exploited the use of cell-permeable αKGlogues to 
provoke the increase of the physiological substrate of PHDs feeding their activity. Indeed, it 
is well known that the slightest fluctuations in αKG levels feeds the PHDs reaction (Km 
around 50µM). Hence, we generated a panel of 7 novel αKGlogues that maintain their 
structural integrity both in organic solvents and in aqueous solution. We screened the 
analogues, to assess their ability to stimulate HIF-1α degradation under hypoxic conditions 
and to consequently impair cancer cells proliferation without exerting broad cytotoxicity on 
non-cancer controls. Consequently, only the most selective compounds displaying the least 
toxic side-effects on the non-cancer cells were considered for further investigations.  
Surprisingly, testing the 7 analogues on thyroids carcinoma (TPC-1) and kidney carcinoma 
(UOK-257) cell lines revealed different sensitivities in terms of HIF-1α degradation. We 
observed that while TPC-1 cells responded more to 200µM of αKG-tB, αKG-N, αKG-Cl, 
αKG-L and αKG-G, UOK-257 cells were more sensitive to αKG-PP, αKG-Cl, αKG-P, αKG-
N and αKG-G, to a lesser extent. Such a disparity between the two cancer cell models may be 
attributed to each cell respective membrane composition, which make them more permeable 
to some analogues harbouring specific hydrophobic groups and less to others. In this regard, 
the commercial αKG-DM is unable to influence HIF-1α expression levels which remained as 
high as the untreated control in UOK-257 cells whereas the same dose of compound 
significantly reduced HIF-1α abundance 60 and 90 minutes after exposure in TPC-1 cells. 
77 
 
Such results thus suggest UOK-257 cells membrane permeability is more selective compared 
to TPC-1. Moreover, the rate of delivery and use of the compounds which likely varies from 
one cell to another based on their metabolic profile could strongly influence the analogues 
intracellular kinetics. This can account for the transient effect observed with αKG-N and 
αKG-P in UOK-257 cells suggesting these compounds have a short half-life and possibly 
they are quickly metabolized following cell uptake. Indeed, in a study carried out by Tennant 
and collaborators, the authors reported a peak in αKG intracellular levels as early as 45 
minutes following αKG-analogues administration, after which the metabolite’s concentration 
rapidly decreased to reach the baseline at 120 minutes. Interestingly, structure optimisation of 
monoester TαKG to produce diester ETαKG was able to prolong αKG accumulation inside 
the cells up to 4h thereby directly linking the analogues structure with their ability to 
maintain steady delivery of αKG to the cell (Tennant et al., 2009). It is worth to add that in 
our tested cancer cell models, un-conjugated αKG was unable to affect HIF-1α protein levels 
under hypoxic conditions further confirming similar observations by Gottlieb and his group 
(MacKenzie et al., 2007; Tennant et al., 2009) who showed free αKG inability to cross the 
plasma membrane as reflected by unchanged metabolite’s intracellular levels.  
In light of the screening results, we were able to select 4 analogues on the thyroid carcinoma 
cell line namely, αKG-N, αKG-L, αKG-tB and αKG-Cl, and 5 for the kidney carcinoma cells 
(αKG-G, αKG-N, αKG-Cl, αKG-P and αKGPP), based on their respective abilities to induce 
HIF-1α degradation under hypoxic conditions. Next, we investigated the effect of the selected 
compounds on cancer cells proliferation in a context of HIF-1α destabilisation. In this regard, 
200µM αKG-G, αKG-N and αKG-L showed little or no effect on the proliferation of thyroid 
carcinoma cells (TPC-1) nor on the non-cancer thyroid epithelial cells (N-Thy 3.1) up to 72h 
under hypoxic condition. Similarly, we noted that αKG-G and αKG-N or αKG-P were unable 
to affect the growth of the kidney cell models up to 200µM independently from oxygen 
conditions. These analogues showed a transient effect on HIF-1α protein expression which 
was recovered after 90 minutes of treatment, potentially hinting that the compounds display 
an early biological effect on HIF-1α protein levels which is overcome due to the fast use of 
the metabolite. Interestingly, in the literature αKG analogues were reportedly used at 
concentration ranging from 2mM to 5mM, albeit at least 10 times more than in the present 
study. In light of PHDs affinity for their substrate (Km around 50µM), this might account for 
the low potency of doses as small as 2µM and 20µM which maybe too weak to influence the 
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hydroxylases activity, further highlighting the necessity to use doses at least equal or superior 
to αKG physiological levels in order to observe a biological effect.  
In addition, we show that αKG-Cl displayed a dose-dependent effect on the proliferation of 
both TPC-1 and UOK-257 cells with doses as low as 2µM ultimately resulting in a blocked 
proliferation at 200µM independently of oxygen tension, suggesting the analogue’s effect on 
cell growth is likely independent from HIF-1α status. Such an observation could be due to an 
off-target effect or attributed to the activity of the hydrophobic carrier per se. Overall, despite 
being well tolerated by the epithelial kidney cells, this analogue severely hampered the 
growth of the non-cancer thyroid cells at 200µM and was therefore discarded from the study. 
These results highlight the sensitivity to different treatments is strongly related to the cells 
tissue of origin, a parameter often recognised to further complicate the development of anti-
cancer therapies. 
Although it is well known that coupling αKG to hydrophobic groups enhances its membrane 
permeability, however, the possibility that these carriers alone, may display a biological 
activity cannot be excluded. In this regard, we show that αKG-tB selectively hampered the 
growth thyroid carcinoma cells and in vitro tumorigeneic properties at 200µM without 
inducing marked toxicity on the non-cancer N-Thy 3.1 cells up to 72h of treatment. However, 
despite its high potency in recreating a pseudonormoxic state up to 12h of exposure (Figure 
18A-C) we were able to demonstrate that the anti-proliferative effect of αKG-tB on the 
thyroid cancer cells was independent from HIF-1α destabilisation and is, instead solely due a 
non-specific activity of the hydrophobic carrier tB, thereby leading to its exclusion. Hence, at 
the term of the screening phase and based on each analogue’s effectiveness and safety 
properties which constituted our main criteria in this study, αKG-PP was selected as the most 
promising hit and all the other analogues were discarded.  
Indeed, the potential of αKG-PP lied in its ability to impair the growth of the kidney 
carcinoma cells at 200µM ultimately leading to cell death with good safety levels on the 
kidney epithelial counterparts under hypoxic conditions, overall correlating with a sustained 
HIF-1α destabilisation at long term and the repression of cancer cells in vitro clonogenic and 
migration abilities. Further, taking advantage of HIF-TM overexpressing cells, we were able 
to establish a direct link between αKG-PP treatment, HIF-1α expression and altered cancer 
cells growth. We demonstrated that the growth alteration provoked by αKG-PP in UOK-257 
cells is in part dependent on blocked HIF signalling, the other part being due to a synergistic 
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activity of the PP carrier independently from HIF-1α status. To our knowledge, this is the 
first time the single activity of the carriers is reported unveiling an additive effect on cancer 
cells growth and tumorigenic properties. We provide evidence that exposure to αKG-PP and 
not PP carrier specifically blocked HIF-1α stabilisation in UOK-257 cells. At the intracellular 
level, this correlated with a peak in αKG concentration 1 and 3h post-treatment culminating 
in increased αKG/SA ratio. Consistently with former studies, these data give further insight at 
two levels: first by confirming the ability of our synthetised analogue to permeate through the 
plasma membrane and cause the accumulation of the ketoacid inside the cells (Mackenzie et 
al., 2007; Tennant et al., 2009). On the other hand, and as previously emphasized, a high 
αKG/SA is one of the main features of CI-deficient cells thus confirming our initial 
hypothesis that αKG supplementation is able to recapitulate some features of CI-deficient 
cells, namely a high αKG /SA ratio together with chronic HIF-1α destabilisation.  
Besides αKG accumulation, metabolomics data revealed oncometabolite 2-HG levels 
remained stable 3h post-treatment indicating that the exogenous αKG is quickly metabolised. 
On the other hand, the low levels of SA coupled to an increased malate/aspartate ratio, a 
direct indicator of NADH accumulation, hint to the reduction in the oxidative flux of the 
TCA cycle usually endorsed by αKGDHC. Indeed, the activity of the enzymatic complex is 
known to be negatively regulated by increased NADH/NAD+, especially in a context of 
severe mitochondrial defects (Calabrese et al., 2013) (Vatrinet et al., 2017). However, further 
analysis is likely warranted to clearly sustain these observations. At the metabolic level, other 
works reported ester analogues of the ketocid to reverse the glycolytic profile characterising 
hypoxic cancer cells, by reducing their glucose consumption and lactate production in vitro 
and in vivo to finally converge in PHD3-mediated apoptotic cell death (Tennant et al., 2009) 
(Tennant and Goettlieb 2010). Independently of HIF-1α and far from its effect in a hypoxic 
context, αKG-DM, a commercial ester analogue, was recently reported to induce synthetic 
lethality in a panel of cancer cells when combined to a well-known OXPHOS inhibitor, 
namely BAY87-2243. In addition to blocking oxidative phosphorylation, the drug 
combination displayed a synergistic effect to suppress glycolysis through a mechanism 
involving MDM2 transcriptional response culminating in a bioenergetic crisis and triggering 
cell death in a panel of cancer cell models (Sica et al., 2019). More recently, a strong line of 
evidence highlights the anti-tumorigenic activity of the ketoacid mediated through the 
stimulation of other dioxygenases of the αKGDDs family, namely DNA and histone 
demethylases TETs and KDMs ultimately reversing pro-tumorigenic epigenetic signals. In 
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this regard, αKG-DM was described to recapitulate p53 transcriptional response and favour 
cell differentiation via the reactivation of TETs enzymes in a model of pancreatic ductal 
adenocarcinoma (Morris et al., 2019).  
In our hands, although UOK-257 exposure to αKG-PP or PP carrier induced a cytotoxic cell 
death, cells showed no morphological features of apoptosis, thus indicating the analogue and 
carrier anti-proliferative activity is mediated through a different mechanism. Similarly, αKG-
PP did not trigger senescence nor autophagy in the kidney carcinoma cells. Instead, the 
supplementation of the ketoacid seemed to mediate a rapid repression of mTORC1 signalling. 
These data suggest that in addition to inducing a state of pseudonormoxia, the intracellular 
accumulation of αKG secondary to treatment also correlated with the inhibition of mTOR 
signalling, potentially accounting for the growth arrest observed in these cells. Interestingly, 
mTOR signalling cascade is well known to act upstream of HIF-1α thereby promoting HIF1A 
mRNA transcription and translation (Iommarini et al., 2017). Hence, by downmodulating 
mTORC1 pathway, it is possible that exogenous αKG indirectly potentiates its repressive 
activity on HIF-1α expression. In addition, preliminary data at longer terms revealed that 
αKG-PP-mediated mTORC1 repression is maintained over time and in such a context, PP 
carrier per se also appeared to contribute to the downregulation of the mitogenic pathway 
further confirming its synergistic activity on cell growth as previously related. Analogous 
effects were described during the response to pro-apoptotic and cytotoxic compounds like 
staurosporine, which reportedly inhibited mTOR-dependent protein synthesis by directly 
acting on its downstream targets (Tee and Proud 2001). Similarly to staurosporine, treatment 
with αKG was shown to impair the proliferation of colon adenocarcinomas cell lines by 
inducing cell cycle arrest in normoxia (Rzeski et al., 2012). It is therefore possible that αKG-
PP and PP carrier block cell cycle progression by inactivating mTOR downstream targets and 
shutting down protein synthesis to finally trigger cell death. In this regard, αKG accumulation 
may induce an immediate cell death following the double repression of HIF-1α and mTOR 
signalling while the PP carrier may provide a late additive effect thereby sustaining cell 
death. Nevertheless, further investigations are ongoing to confirm the previous observations 
and clearly determine the mechanisms underlying αKG-PP and PP carrier anti-proliferative 
activity in other cancer cell models.  
To conclude, the pleiotropic implication of the metabolite highlights its multiple targets and 
thus considerably widens the scope of its therapeutic applications. This study sustains 
previous reports in shedding light on the great potential αKG holds to modulate cancer 
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progression. At the present time, no clinical studies have included αKG as a therapeutic agent 
in the context of cancer and studies have been restricted to murine models so far. On the other 
hand, thanks to the preservation of signaling pathways from human to flies and their facility 
of use, Drosophila constitutes an excellent model for drug screening studies. In this regard, 
our preliminary data confirmed the anti-proliferative activity of αKG-PP in vivo on a 
Drosophila cancer model thereby strengthening the anti-tumorigenic potential of αKG 
analogues and paving the way to further studies. The encouraging results presented herein 
along with those increasingly reported in literature support the hypothetic anti-cancer activity 
of the ketoacid and open the possibility to the application of an αKG-based therapy in 
combination with conventional or novel chemotherapeutic drugs in the frame of a synthetic 
lethality approach, however, before considering the translation in cancer patients in the clinic 
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